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Thyroid cancer is the most common endocrine malignancy. Around 20% of 
thyroid cancer cases involve tumors that are poorly differentiated. 
Undifferentiated tumors grow rapidly and exhibit dysregulated cell cycle control 
and apoptosis. In the past decade there are many researchers focusing on the 
development of anticancer agents in order to target the poorly differentiated and 
undifferentiated thyroid cancer. 
Peroxisome proliferator-activated receptor gamma (PPAR) is a member of the 
nuclear hormone receptor superfamily. PPAR y is involved in cell cycle control 
and apoptosis in cancer cells, and the activation of PPAR plays an inhibitory role 
in cell proliferation and growth. Previous studies from our laboratory have shown 
that the proliferation of thyroid cancer cells is regulated by estrogen (E2) and its 
receptors (ER). ERa is positively associated with thyroid cell proliferation and in 
contrast, ERp negatively associated with the proliferation. Thus, the aim of this 
study was to explore whether there was a link between ER and PPAR 7 in thyroid 
cancer cells. 
I 
In order to investigate the effects of peroxisome proliferator-activated receptor 
gamma (PPARy) by PPT and DPN in human thyroid carcinoma cell lines (NPA 
and FRO). NPA and FRO cells were treated by ERa agonist PPT (10-6M) for 48 h 
to increase the level of ERa and by ERp agonist DPN (10-6M) to promote ERb. 
Cell proliferation was measured by using the MTT assay. PPARy activity was 
measured by transient transfection assay and the 15d-PGJ2, 15S-HETE and 13S-
HODE enzyme immunoassay. Apoptosis was characterized by Cell Death 
Detection ELISAplus assay. The expression of PPARy was measured by the 
Western blot analysis. 
Results: ERa enhanced the proliferation of thyroid cancer cells and thus 
reduced the apoptosis. Unlike ERa, ERp inhibited the cell proliferation and 
promoted the apoptosis. After 48h-treatment, PPT decreased the levels of PPARy 
ligands (15d-PGJ2, 15S-HETE and 13S-H0DE) but DPN increased the levels of 
PPARy ligands (15d-PGJ2, 15S-HETE and 13S-H0DE). The PPARy transient 
transfection experiment showed that PPT treatment has no effect on the activity of 
PPARy but DPN enhanced it. 
In conclusion, PPT, the ERa agonist, can increase thyroid cancer cell 
proliferation probably via decreasing the level of PPARy ligands (15d-PGJ2, 15S-
HETE and 13S-H0DE) whereas DPN, the ER(3 agonist, induced apoptosis by 
increasing the PPARy transcriptional activity and/or by increasing the PPARy 
ligands. Therefore, it is possible that ER agonist and ER antagonist, PPT and 
DPN, may regulate the proliferation or apoptosis of thyroid cancer cells via a 








表明， P P A R Y在肿瘤细胞的细胞周期和调亡中占据重要作用， P P A R Y的激 
活可以抑制肿瘤的生长和增殖。本实验室以前的研究亦表明，雌激素 (E)和 
雌激素受体 (ER)可以明显的调节甲状腺癌细胞的增殖。ERA与甲状腺癌细胞 
的增殖成正相关，而E R P与细胞的增殖则成负相关。那么，本研究目的在 
于探明E R和P P A R Y在甲状腺癌发生发展中是否具有相关性。 
为了明确P P A R Y在甲状腺癌中的作用，我们用两种甲状腺癌细胞株 ( N P A和 
F R O )作为研究对象，分别用 E R A的激动剂 P P T ( 1 0 _ 6 M ) 和 E R | 3 激动剂 D P N 
(l(r 6M)处理48h后提高ERa和ERp的水平。用MTT法检测细胞增殖；用 
瞬时转染测定法和 1 5 d - P G J 2酶免疫分析法检测 P P A R Y活性；用细胞死亡 
ELISA试剂盒检测细胞调亡；PPARY蛋白的表达则用Western Blot方法检 
测。 
结果显示： E R a促进细胞增殖降低凋亡的发生。与 E R a不同的是， E R p抑 
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1.1.1 Thyroid cancer 
Thyroid carcinoma is a rare malignancy, accounting for less than 1% of human 
malignant neoplasms. In the endocrine system, however, it is the most common 
malignancy and is responsible for more deaths than all other endocrine cancers 
combined. There are four types of thyroid cancers: 1) Papillary thyroid carcinoma 
(�78%) , 2) Follicular thyroid carcinoma (-17%), 3) Medullary thyroid carcinoma 
( � 4 % ) and 4) Anaplastic thyroid carcinoma (�1%) . The degree of malignancy of 
the different types of thyroid cancer is often categorized according to their levels 
of differentiation. The more differentiated the thyroid cancer is, the more it 
resembles the normal thyroid tissue, and therefore the more treatable it is (i.e. the 
less malignant it is). Papillary and follicular cancers are referred to as well-
differentiated thyroid cancers. These cancers account for about 90% of thyroid 
cancers and are usually associated with the best outcomes mainly because they 
tend to grow very slowly particularly in young patients. Anaplastic cancer is often 
called undifferentiated because it least resembles the normal thyroid tissue. It is a 
very rare type of thyroid cancer which is very aggressive and is associated with a 
poor prognosis. Annual incidence is varying by geographic area, age, and sex. 
Approximately 500 new cases of thyroid cancer are now diagnosed annually in the 
Hong Kong with a female:male ratio close to 4:1 (www3 .ha.org.lik/cancereg/). 
Thyroid cancer is very rare in children under age 15 and the annual incidence of 
thyroid cancer increases with age, peaking between 9.5 to 11.5 per million by the 
fifth through eighth decades (www3.ha.org.hk/cancereg/). There are 500 new 
2 
cases are reported each year in the Hong Kong, however, the annual mortality 
from thyroid cancer is low—0.5 deaths per million individual per year 
(www3 .ha.org.hk/cancereg). It presumably reflects the good prognosis for most 
thyroid cancers. Mortality rates are lowest in individual under age 50 and increase 
sharply thereafter. There are about 39 deaths from thyroid cancer annually in the 
Hong Kong, accounting for 0.33% of all cancer deaths 
(www3.ha.org.hk/cancereg). The difference in incidence between the genders 
suggests that the growth and progression of thyroid tumors is influenced by 
female sex hormones, particularly estrogen, which is implicated in the 
development and progression of numerous cancers, such as breast and ovary. 
Previous study from our laboratory has shown that estrogen helps to regulate the 
proliferation and apoptosis of thyroid cancer cells and induces different cellular 
responses by binding to the estrogen receptor (ER) proteins, ERa and ERp, which 
are members of a large superfamily of nuclear receptors. Other than estrogen 
receptors (ERs), there is another nuclear receptor called peroxisome proliferator-
activated receptor gamma (PPARy), has received much attention in these years in 
the treatment of thyroid cancers. In the past decade, there has been a dramatic 
increase in the development and study focusing on the PPARy in order to target 
the poorly differentiated and undifferentiated thyroid cancers. Since the both 
receptors ER and PPARy are involved in the regulation and proliferation of 
thyroid cancer, whether there is a linkage between ER and PPARy in thyroid 
cancer cells is the focus of the ongoing research. 
3 
1.1.2 Apoptosis and thyroid cancer 
In the normal thyroid gland, total cell mass is maintained constant by a balance 
between cell proliferation and apoptosis. In thyroid cancer cells, this equilibrium 
is disrupted, resulting in an increased growth rate and tumor formation. Study of 
Broecker et al (1999) demonstrated that cytotoxic drugs increase the expression of 
the pro-apoptotic protein bax and decrease the expression of antiapoptotic protein 
bcl-2 in benign primary thyroid cells, but not in undifferentiated thyroid 
carcinoma cells. Therefore, the poor response of thyroid cancer cells to cytotoxic 
drugs may at least partly be explained by an altered regulation of apoptosis in 
thyroid cancer. 
Apoptosis or programmed cell death is an active process in which a cell dies for 
the benefit of the whole organism; this mode of cell death is critical in the 
development and maintenance of multicellular organisms. Apoptosis is 
characterized by specific morphological features. The process starts with 
chromatin aggregation along the inner walls of the nuclear envelop and is 
followed by cytoplasmic shrinkage and extensive DNA degradation. Then, the cell 
condenses into membrane-bound fragments that are eliminated by surrounding 
macrophages without an inflammatory reaction. Apoptosis is an important process 
in carcinogenesis and is an important response to anticancer treatments for thyroid 
tumors. Thyroid cancer has been associated with alternations in an increasing 
number of apoptotic molecules. During the development of cancer, cancer cells 
and their precursors must develop highly efficient and multiple mechanisms in 
4 
order to avoid apoptosis. Therefore, aborting apoptosis is regarded as one of the 
hallmarks of cancer cells. 
1.2 Estrogen receptors and apoptosis 
1.2.1 Estrogen receptor-a (ERa) and Estrogen receptor-p(ERp) 
Estrogen receptors (ERs) is one of the most important molecular factors which 
used to predict the prognosis and response to therapy of thyroid cancer patients. 
ERs are members of the nuclear receptor (NR) superfamily that mediates the 
effects of the steroid hormone estrogen in a diverse range of physiological 
processes. Estrogens regulate growth, differentiation, and homeostasis in 
eukaryotic cells but have been associated pathologically with a higher risk for 
thyroid cancer (Shao W et. al.，2004). In fact, thyroid cancer hormone dependence 
is correlated with tumor progression and patient prognosis (Lapidus RG et al., 
1998). As such, tumor ER expression plays an important role in the clinical care of 
thyroid cancer patients as a prognostic factor and therapeutic target. ER absence is 
correlated with a more malignant disease and poor prognosis. Binding of 17-P-
estradiol (E2) to the active form of ERs induces tumor growth in ER-positive 
thyroid cancers. Therefore, reducing estrogen levels or altering the activity of the 
receptor can induce these cancers to regress. E2 action involves ligand-mediated 
activation of nuclear ERa and ERp，which interact directly with estrogen response 
elements (EREs) in the promoter and/or enhancer regions of target genes and 
recruit various coactivators to mediate transcriptional regulation (McDonnell DP 
et. al., 2002). 
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To date, two isoforms of ER (ERa and ERp) have been identified, encoded by 
independent genes. Both ER isoforms show modular structure characteristics of 
the NR superfamily and, although both ERa and ERp display similar binding 
affinities for E2, they have different roles in the regulation of gene expression 
(Shao W et. a l , 2004). 
1.2.2 Differential roles of estrogen receptors-alpha(ERa) and estrogen 
receptors-beta (ER p) in apoptosis 
Our previous study demonstrated that both estrogen receptors (ER) a and p 
existed in thyroid cancer cells (Lee et. al.，2005). ERs are expressed in different 
parts of thyrocyte and by different types of thyroid cells. ERa immunoreactivity is 
not detected in the nucleus of follicular cells in developing fetal thyroid glands, 
however, ERa immunoreactivity is detectable in the nucleus of parenchymal cells 
in thyroid disorders (Kawabata et al , 2003). The expression of ERa mRNA is 
notable in follicular adenomas and medullary carcinomas and similar levels have 
been seen in papillary and follicular carcinomas (Egawa et al.，2001). Estradiol 
has been shown to stimulate the proliferation of FRTL-5 rat cells, a well-
established cell line derived from thyroid papillary carcinoma (Furlanetto et a l , 
1999). Studies from our laboratory have shown that there is significant association 
between estrogen and cell growth in human papillary thyroid carcinoma KAT-5 
cells. It suggested that increased concentration of estrogen may responsible for the 
relatively increased incidence of papillary thyroid carcinoma in premenopausal 
women. 
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ERp nuclear immunoreactivity has been detected widely in follicular, papillary 
thyroid cells. The estrogenic effect via ERp plays a role in the maintenance of 
homeostasis of thyroid follicles, and possibly of thyroid hormone biosynthesis 
(Kawabata et al.，2003). Studies from our laboratory have shown that an increase 
in ERp contributed to apoptosis in KAT-5 cells, suggesting that ERp may 
responsible for inhibiting cell proliferation. ERp is a negative modulator of cancer 
cell proliferation and invasion, supporting the concept that a loss of ERp 
expression could cause the development of cancer cells and the alternations in the 
ratio of ERa to ER(3 may govern tumor development (Lazennec G et al., 2001). A 
decrease in ER(3 mRNA is inversely correlated with tumor progression when 
compared to ERa mRNA, the ratio of ERa mRNA to ERp mRNA is markedly 
increased in ovarian cancer (Cunat et a l , 2004). 
Both receptors ERa and ERp bind E2 with the same affinity, but they can activate 
certain promoters differentially. Studies have shown that ERa is the primary 
endogenous mediator that responsible for E2 to promote proliferation and survival 
(Clarke et. al., 2003). In contrast, ERP acts as a negative modulator of ERa 
activity and promotes cell death. In recent years, much effort has been invested in 
the development of ERa- and ERp-specific agonists and antagonists. Several such 
compounds have been developed, one of the ERa-specific agonists, 4,’，4，，-(4-
propyl(lH)-pyrazole-l,3,5-triyl)trisphenol (PPT), has been shown to stimulate 
proliferation and its binding affinity is 410-fold more potent in binding to ERa 
than ERp (Stauffer et al., 2000). In the other hand, one of the ERp-agonists, 2.3-
bis(4-hydroxy-phenyl)-propionitrile (DPN) has been shown to inhibited cell 
growth and induced apoptosis, it binds to ERp with an affinity 72-hold higher than 
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to ERa (Meyers et a l , 2001). As ERa and ERp have opposing cellular responses 
and both ERa and ERp are functional, the tendency for cells to promote 
proliferation or to induce apoptosis is dependent on the binding affinity of ERa 
and ERp. According to the study of Heiguero et al., it showed that PPT caused an 
increase in cell number of nearly 50% while DPN caused a decrease of 30% 
compared to the untreated cells (Heiguero et al, 2005). Both PPT and DPN had 
positive effects on cell metabolism, however, activation of ERa is independent of 
ERp, and vice versa. 
1.23 Bcl-2 family 
Bcl-2 plays an important role in the promotion of thyroid cancer cell growth. High 
levels of Bcl-2 and Bcl-xL, both of which are antiapoptotic, are found in 
malignant epithelial cells from PTC, FTC and ATC and the level of proapoptotic 
Bax is reduced in thyroid cancer (Stassi G et a l , 2003). The aberrant expression of 
Bcl-2, Bcl-xL, and Bax is thought to result from a change in the cytokine 
environment of the thyroid, especially interleukin(IL)-4 and IL-10. Obviously, the 
changes in Bcl-2 family members disturb the balance between proapoptotic Bax 
and antiapoptotic Bcl-2 and Bcl-xL, thereby reducing the sensitivity of thyroid 
cancer cells to apoptotic stimuli. Bcl-2 proteins localize or translocate to the 
mitochondrial membrane and modulate apoptosis by permeabilization of the inner 
and/or outer membrane, leading to the release of cytochrome c. The anti-apoptotic 
protein Bcl-xL binds and inactivates the caspase adapter. This anti-apoptotic 
effect is balanced by pro-apoptotic Bcl-2 proteins (Gross et al., 1999). 
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Expression of anti-apoptotic protein Bcl-2 is increased by estradiol in estrogen-
responsive MCF-7 cells. Some studies suggest that high levels of Bcl-2 and low 
levels of Bax correlate with decreased protease activity in MCF-7 variants (Burow 
et al., 1998). 
Bcl-2 family members are known to be altered in thyroid cancer and their levels 
are known to be regulated by estrogen in some cell system (Song et al.,2003). 
Previous studies from our laboratory showed that the anti-apoptotic protein Bcl-2 
was up-regulated by estradiol and ERa agonist PPT but down-regulated by ERp 
agonist DPN in KAT-5 cells. It suggested that ERa induced Bcl-2 expression 
whereas ER(3 reduced it. The role of estradiol and ERa in the expression of Bcl-2 
was further supported in which the up-regulatory effect of estradiol was prevented 
by both the general ER antagonist ICIl82780 and the ERa-selective antagonist 
MPP. In contrast to Bcl-2, the pro-apoptotic protein Bax was increased by DPN 
while there is no obvious effect in the level of Bax when treated with estradiol and 
PPT. These results suggest that ERp and not ERa protein the level of Bax. 
1.3 Perioxisome proliferator-activated receptors-y (PPARy) 
1.3.1 Molecular Aspects of PPAR 
Perioxisome proliferator-activated receptors (PPARs) are the latest members of 
the nuclear hormone receptor superfamily discovered to play a role in 
carcinogenesis. Originally identified by their role in the terminal differentiation of 
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adipocytes, the ligands for these receptors were subsequently shown to induce 
differentiation of breast cancer cells in vitro (Mueller E et.al•，1998). Three 
distinct isoforms are known: a, p, and y. 
The mouse and human PPAR genes characterized to date reveal a common 
organization of the translated region in six coding exons with the following 
distribution: one exon for the N-terminal A/B domain, two exons for the DNA-
binding domain (DBD)-one for each of the two zinc fingers, one exon for the 
hinge region, and two exons for the ligand-binding domain (LBD). The mouse 
PPARa gene spans at least 30 kb and comprises a total of eight exons, with two 
exons corresponding to the 5'-untranslated region and the last exon of the LBD 
comprising the 3'-untranslated region (Gearing KL et al., 1994). For the PPARp 
gene, only a partial organization in Xenopus, which corresponds to the six exons 
of the translated region, has been reported so far (Krey G et a l , 1993). The human 
and mouse PPARy genes extend over more than 100 kb of genomic DNA and give 
rise to three mRNAs，PPARy 1, PPAR72, and PPARy3, that differ at their 5'-end as 
a consequence of alternate promoter usage and splicing (Figure 1.1). PPARy 1 is 
encoded by eight exons, comprising two 71-specific exons for the 5'-untranslated 
region, Al and A2, and the six coding exons that are common to all three mRNAs. 
PPARy2 is encoded in seven exons, the first one, exon B, comprising the j2 5'-
untranslated region and encoding additional N-terminal amino acids specific of y2. 
On genomic DNA, this 丫2-specific exon is located between the second mPPARyl 
exon (A2) and the first common exon (Zhu Y et al., 1995). A third mRNA, 
PPARY3, encodes the same protein as P P A R Y 1 but is controlled by an alternative 
promoter located in the region flanking exon A2 in 5' (Fig. 1) (Fajas L et al., 1998). 
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Alternate transcription sites and alternate splicing determine three PPARy mRNA 
isoforms sharing exons 1-6 and differing in the 5'end. (Greene ME et. al.，1995). 
11 
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Figure 1.1 hPPARl isoforms. 
The genomic organization of the hPPARl gene is shown. Two PPARl isoforms are 
produced by the differential use of three promoters and alternative splicing of the 
three 5'-exons Al, A2, and Bl. Exons 1-6 are common to all three transcripts. A 
scheme of the three mRNAs obtained is drawn, and the size of the proteins 
obtained is indicated. Note that transcription from the promoters V and 15 results 
in the same protein of 477 amino acids. In the human gene, the splicing event 
between exon A2 and exon 1 generates an AUG translation initiation codon six 
nucleotides upstream of the one used in other species, which is located at the very 
beginning of exon 1. Therefore, the hPPARll protein has two additional amino 
acids at its N terminus compared with the rodent PPARll protein. The PPAR12 
protein of 505 amino acids is produced by transcription from the promoter X2. 
The number of additional N-terminal amino acids in PPAR12 PPARll is 28 in 
humans and 30 in rodents. 
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1.3.2 PPAR/RXR complex 
The DNA binding domain is the most conserved domain between all nuclear 
receptors, and indeed is the hallmark of the superfamily. It is formed by two zinc 
finger-like motifs folded in a globular structure that can recognize a DNA target 
composed of 6 nucleotides. In most cases, nuclear hormone receptors bind as 
dimers to two copies of such a core motif, which constitute a functional hormone 
response element. The spacing of the two motifs and their relative orientation {i.e., 
direct repeat, palindrome, or inverted palindrome configurations) determine which 
receptors bind to a given hormone response element (Glass CK et al , 1994). 
Members of the Thyroid Hormone Receptor (TR)/retinoic acid receptor(RAR) 
subfamily to which PPARs belong recognize preferentially the core 
hexanucleotide motif AGGTCA and are also characterized by the ability of 
forming a heterodimer with the 9-cz5-retinoic acid receptor, RXR. In fact, PPARs 
bind neither as homodimer nor as monomer but strictly depend on RXR as DNA 
binding partner (figure 1.2) 
The fact that some tissues expressing more than one PPAR isotype raises the 
question of PPAR isotype-specific PPRE recognition. Assessment of the relative 
DNA-binding capabilities of the three PPAR isotypes (a, p, y) to 16 native PPREs 
led to the classification of PPREs into three functional groups: strong, 
intermediate, and weak elements, which correlates with the level of the PPRE 
conformity to the consensus element (Juge-Aubry C et a l , 1997). PPARy binds 
more strongly than do PPARa and PPARp and is thus less dependent on a well 
conserved 5'-flanking extension. In contrast, conservation of the 5'-flaiik is 
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particularly essential for PPARa binding and therefore contributes to isotype 
specificity. The PPAR DNA-binding activity is also modulated by the isotype of 
the RXR heterodimeric partner. Binding of PPAR:RXR to strong elements is 
reinforced when RXRy is the partner, whereas heterodimerization with RXRa is 
more favorable for binding to weak elements. However, it remains to be seen how 
these in vitro observations translate into selective recognition of the PPREs within 
their natural genomic and chromosomal environment. 
coactivators corepressors 
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Figure 1.2 A proposed mechanism of PPARy ligands-mediated apoptosis. 
PPARy forms a heterodimer with RXR, and ligation of both receptors is important 
to maximize the signaling. Upon binding to PPARy ligands, the corepressor is 
displaced, the ligand-receptor complex then associates with coactivator 
molecules, and binds to the PPRE located in the promoters of relevant target 
genes such as tumor suppressor PTEN. Induction of expression of PTEN may 
inhibit the anti-apoptotic PI3-kinase pathway. 
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Expression of the three isoforms is tissue-specific. For example, 
Thiazolidinediones (TZD), a class of drugs used to treat diabetes, act by binding 
to PPARy. PPARy is involved in a wide range of cellular processes. It plays a 
central role in controlling the expression of numerous genes involved in 
adipocytes differentiation, lipid storage, and insulin sensitization. PPARy is 
activated by its natural ligands, for example, prostaglandin J2 and fatty acid 
derivatives, however, thiazolidinediones and nonsteroidal anti-inflammatory drugs 
are synthetic ligands and agonists of these receptors (Krey G et. al., 1997). 
However, PPARy has much wider functions, being involved in cell cycle control, 
inflammation, atherosclerosis, apoptosis, and carcinogenesis. PPARy agonists 
induce apoptosis in several types of cancer cells, and the known mechanisms for 
this action include upregulation of GADD153, c-jun, Bax, and Bad, 
downregulation of Bcl-2, and activation of caspase 3 in several types of cancerl 
cells (Kim et al., 2003). Studies on thyroid carcinoma with PPARy agonists 
treatment focus mainly on the induction of apoptosis. In thyroid carcinoma cells, 
PPARy agonists induced apoptosis is dependent on upregulation of p21, p27, or c-
myc, but independent of the expression of Bcl-2 or Bax (Ohta et a l , 2001). 
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1.3.3 PPARy ligands 
The ability of PPARy to regulate cell differentiation and proliferation has 
attributed to the exploration of the use of PPARy agonists as chemotherapeutic 
agents. PPARy ligands have been shown to inhibit growth and induce terminal 
differentiation of cancerous cells. In common with other members of the nuclear 
receptor gene family, the PPARs function as ligand-activated transcription factors, 
forming heterodimer with the retinoid X receptor (RXR) (P.H. Koeffler et al., 
2003). PPARy ligands, including the antidiabetic thiazolidinediones, certain fatty 
acids and metabolites of arachidonic acid. 
Eicosaiioids are a class of fatty acids mainly derived from arachidonic acid, either 
via the lipoxygenase pathway leading to the formation of leukotrienes and 
hydroxyeicosatetraenoic acids (HETEs) or via the cyclooxygenase pathway 
producing prostaglandins (PGs). Several of these eicosanoids are activators of the 
different PPARs, and some are indeed ligands. 15-Deoxy-A 12,14-PGJ2, which is 
a PGD2 derivative, is a ligand for PPARy and 15(S)-HETE and 13(S)-H0DE, 
compound associated with phorbol ester-induced inflammation, are also ligands 
for PPARy (Figure 1.3-1.5). 
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Figure 1.3 Structure of 15-deoxy-Deltal2,14-Prostaglandin J2. 
15-d-PGJ2 is one of the ultimate dehydration products ofPGD2. PGD2 is formed 
from PGH2 which itself is synthesized from arachidonic acid by the enzyme 
prostaglandin synthetase. In the aqueous solution PGD2 forms PGJ2. 15-d-PGJ2 
has been shown as an inducer of adipogenesis and an activator of the gamma 




Figure 1.4 Structure of 13-hydroxyoctadecadienoic acid. 
The major human dietary poly-unsaturated fatty acid is linoleic acid, an essential 
fatty acid that can be metabolized to either 13-hydroxyoctadecadienoic acid via 
the lipoxygenase [13(S)-H0DE] or P450 [13(R)-H0DE] pathways or to 15-
hydroxyeicosatetraenoic acid [15(S)-HETE] via the cyclooxygenase pathway. 
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Changes in the intra-cellular ratio of 13(S)-H0DE to 15�-HETE have been 
linked to a number of physiological conditions dominated by cancer and 
cardiovascular diseases. 13�-HODE helps to mediate cellular adhesion 
properties and excessive proliferation that is critical in the formation of tumors, 
metastasies and artherogenic plaques. 




Figure 1.5 Structure of 15-hydroxyeicosatetraenoic acid. 
15(S)-HETE is the major hydroxy derivative of arachidonic acid when acted upon 
by 15-lipoxygenase (15-LOX). It is also the primary monohydroxy acid 
synthesized by the lipoxygenase activity of Cyclooxygenase-1. Aspirin-mediated 
acetylation of the COX-1 enzyme results in 15(R)-HETE. Interleukin-4 has been 
shown to regulate 15(S)- HETE expression and incorporation into cellular 
phospholipids. 15�-HETE binds to actin and the alpha-subunit of mitochondrial 
ATP synthase suggesting a more direct method in regulating some physiological 
activities. 
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Upon ligand binding, the heterodimer complex of PPAR and RXR binds to 
specific recognition sites on DNA, the peroxisome proliferator response elements 
(PPREs) and regulates transcription of specific genes. The PPAR-y and RXR 
complex, along with other co-activators for transcription, activate transcription of 
target genes. In the absence of a ligand, high affinity complexes are formed 
between the PPAR—RXR heterodimer and nuclear receptor corepressor proteins 
such as nuclear receptor corepressor (N-CoR) or silencing mediator for retinoid 
and thyroid hormone receptors (SMART), suppressing its interaction with DNA 
and coactivators including steroid receptor coactivator-1 (SRC-1), CREB-binding 
protein (CBP) and the CBP homologue p300 (L Gelman 1999). Upon ligand 
binding, the corepressor is displaced, and the receptor then associates with a 
coactivator molecule. The resulting complex binds to PPRE in the promoters of 
relevant target genes. 
The activated PPAR/RXR heterodimer could interact with heat-shock protein-72 
(HSP-72), liver X receptor, PPAR-binding protein (PBP), steroid receptor 
coactivator-1 (SRC-1), integrator protein p300, thyroid hormone receptor-
associated protein (TRAP)/vitamin D3 receptor-interacting protein (DRIP) 
complex, cAMP response element-binding protein (CBP) and growth regulatory 
genes such as c-jun, modulating gene transcription (Lehrke M et a l , 2005). 
1.3.4 PPARy and apoptosis in thyroid cancer 
Peroxisome-proliferator-activated receptor y (PPARy) has recently gained much 
attention for its role in apoptosis and tumor development. PPARy activation is 
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capable of inducing apoptosis, thus inhibiting tumor growth. This activation may 
counteract the uncontrolled proliferation and malignant cell growth through 
induction of apoptosis or promotion of cellular terminal differentiation. In fact, 
PPARy is expressed differently in different types of thyroid cancer cells. A study 
shows that PPARy mRNA and protein are found in about half of FTC but not in 
PTC and multinodular hyperplasias (Kroll TG et a l , 2000). In another study in a 
mouse model of FTC, pathways mediated by PPARy are repressed, whereas other 
antiapoptotic molecules, such as TGF-p and nuclear factor kB (NFk-B), are 
upregulated (Ying H et al., 2003). The alteration of PPARy may serve not only as 
a tumor marker for diagnostic purposes but also as a promising target for cancer 
therapy. Therapies designed to stimulate apoptosis in target cells increasely have a 
central role in the prevention and treatment of human cancer, including thyroid 
caner. For several decades, the classical view of an anticancer drug mechanism 
has relied on the specific interaction of a drug with its target, such as an 
interaction can lead to tumor cell death via its direct effect on the proliferating 
tumor cells. However, emerging data based on an increasing understanding of the 
cell cycle control and apoptosis process indicate that, rather than being 
intrinsically toxic, many anticancer drugs merely stimulate tumor cells to self-
destruction via apoptosis. Some studies have demonstrated that most of the 
anticancer drugs (including those that target DNA replication, DNA integrity and 
cytokines) induce apoptosis in thyroid cancer cells. For example, some extracts 
from traditional Chinese herb medicines have shown a strong antiproliferative 
effect via provoking apoptosis in MTC (Poulaki et a l , 2002). With the 
tremendous amount of knowledge gained about apoptosis, the challenge is how 
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this information can be applied to kill tumor cells selectively while sparing normal 
cells. 
In this regard, some promising therapies for thyroid cancer cells have emerged, for 
example, the application of TRAIL in the treatment of thyroid cancer. TRAIL can 
selectively kill thyroid tumor cells without affecting normal thyroid cells (Ahmad 
et al., 2000). Other than TRAIL, PPARy ligands also appear to be an effective 
class of therapeutic agents for thyroid cancer. Various PPARy ligands, including 
troglitazone, 15 -deoxy-12,14-prostagladin J2 (15d-PGJ2), 13-
Hydroxyoctadecadienoic acid (13-HODE) and 15-hydroxy-eicosatetrenoic acid 
(HETE) have been tested for successful inhibition of thyroid cancer cells by 
inducing apoptosis (Ohta et al., 2001). It seems that normal thyroid cells will not 
be significantly targeted by PPARy because much more is expressed in thyroid 
cancer cells than in their adjacent normal thyroid cells. 
1.3.5 PPARy ligands-mediated apoptotic pathway 
The ligands of PPAR-y include several prostanoids as IS-deoxy-A^ '^^ "^-
prostaglandin J2 (15d-PGJ2), 13-Hydroxyoctadecadienoic acid (13-HODE) and 
15-hydroxy-eicosatetrenoic acid (HETE), metabolites of arachidonic acid. The 
pharmacological ligands for PPAR-y are the thiazolidinediones (TZDs), a class of 
oral antidiabetic agents and a variety of non-steroidal anti-inflammatory drugs 
(NSAIDs) (P. Puddu et al.，2003). PPAR-y ligands exert aiiti-tumoral effects 
through inhibiting cell growth and inducing cell differentiation in several types of 
human malignant neoplasms. 
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There are many studies supporting that PPARy ligands induce apoptosis in several 
types of cancer cells (N. Takahashi et al., 1999). Moreover, PPARy ligands 
significantly inhibited growth of the transplantable tumors derived from breast and 
colon cancer cells in mice (E. Elstner et al., 1998). 15d-PGJ2 attenuated the 
capability of the human breast cancer cell line (MDA-MB231) to induce tumors in 
nude mice (C.E. Clay et al., 1999). Nonsteroidal anti-inflammatory drugs 
(NSAIDs) is able to induce COX-2 expression through the activation of PPARy, 
and the resulting accumulation of PGs, especially 15d-PGJ2, in turn, could cause 
apoptosis which is mediated in a PPARy-dependent or independent manner 
(Figure 1.6). Induction of COX-2 expression by NSAIDs may cause a positive 
feedback loop of PPARy activation in an autocrine and/or paracrine manner. 
15-Deoxy-A 12,14-PGJ2 can also trigger the apoptosis of endothelial cells via a 
PPAR-dependent pathway (Bishop-Bailey D et al., 1999). Studies based on 
malignant cells clearly support the concept of PPARy being implicated in cell 
cycle withdrawal. Primary human liposarcoma cells, which express high levels of 
PPARY (Tontonoz P et al.，1997), can be stimulated to undergo terminal 
differentiation by treatment with PPAR 7 ligands or RXR-specific ligands. 
Simultaneous application of both treatments results in additive stimulation of 
differentiation, which is characterized by stimulation of adipocyte-specific genes, 
intracellular lipid accumulation, and withdrawal from the cell cycle (Tontonoz P et 
a l , 1997). Activation of PPART also induces reduction in growth rate and 
clonogenic capacity of human breast cancer cells in culture. In one of the breast 
cancer cell lines, which express high levels of PPARy, the resistance to TZD was 
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associated with a high MAP kinase activity, which might explain a low PPAR7 
activity due to phosphorylation. Various human colon cancer cell lines express 
PPARl at high levels, and addition of a PPAR7 ligand not only reduces their 
clonogenic growth in culture but also decreases their growth when transplanted in 
nude mice (Brockman J A et al., 1998). 
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Figure 1.6 Proposed pathways mediating the pro-apoptotic effect of 
nonsteroidal anti-inflammatory drugs (NSAIDs) in association with their COX-
2 induction. NSAIDs may induce COX-2 expression through activation of PPARy. 
The resulting accumulation of PGs, especially 15d-PGJ2 could cause apoptosis in 
a paracrine and/or autocrine manner. AA, arachidonic acid. 
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1.4 Previous results from our laboratory 
Previous study from our laboratory has shown that several human thyroid cancer 
cell lines expressed both ERa and ERp, which provides a good model with which 
to investigate the effect of estrogen on the growth of thyroid cells (Lee et al., 
2005). The role of ERa and ERp in the proliferation and growth of thyroid cancer 
cells has been explored by treating with various ER agonists and antagonists. As 
mentioned, E2 has been shown to promote proliferation and growth of KAT-5 
cells and this proliferation could be blocked by an E2 antagonist, ICIl 82780, 
whose binding affinity with ERs is similar to that of E2 (Manole et al., 2001). 
Furthermore, we blocked the ERa specifically by using the ERa-selective 
antagonist, MPP. It showed that the cell proliferation induced by E2 could be 
effectively blocked to a similar level as that by ICIl 82780, that indicated that ERa 
rather than ERp plays a role in cell proliferation. 
In addition, the exact role of ERa and ERp has also been examined by treating 
KAT-5 cells by the two ER-selective agonist, PPT (an ERa-selective agonist) and 
DPN (an ERp-selective agonist). We observed that PPT promoted cell 
proliferation while DPN suppressed it. In the apoptotic study of DPN on thyroid 
cancer cells, it showed that DPN significantly enhanced the amount of DNA 
fragmentation in our previous study. This suggested that ERa and ERp may have 
an opposite functions in the regulation of thyroid cell proliferation. The 
mechanism responsible for the inhibitory effect of DPN and ERp on cell 
proliferation is associated with the ability of DPN to induce apoptosis in thyroid 
cancer cells. 
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Having established the differential roles of ERa and ERp in the proliferation of 
thyroid cancer cells, further investigation of whether ERa and ERp could 
influence the molecular related to cell proliferation and apoptosis have been 
performed by Zeng Q. In this regard, the expression level of anti-apoptotic protein 
Bcl-2 have been tested when treatment with PPT and DPN, data has been shown 
that the anti-apoptotic protein Bcl-2 was upregulated by PPT but down regulated 
by DPN (unpublished data by Zeng Q.). 
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1.5 Summary of previous studies (unpublished data by Zeng Q.) 
1. ERa and ERp are expressed in KAT-5 thyroid cancer cell lines. 
2. MTT assay has showed that PPT {propylpyrazole triol), an ERa-selective 
agonist, promotes cell proliferation in KAT-5 cells, while DPN {2’ 3-bis(4-
hydroxyphenyl) proprionitrile), an ERp.selective agonist, suppress cell 
proliferation in KAT-5 cells. 
3. Apoptotic assay has showed that DPN significantly enhanced the amount of 
DNA fragmentation in KAT-5 cells, which to prove that DPN is involved in 
induction of apoptosis in thyroid cancer cells. 
4. The expression level of Bcl-2 proteins is increased when treated with PPT and 
it is decreased when treated with DPN. 
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1.6 Perspectives 
Previous studies from our laboratory have shown that the proliferation of thyroid 
cancer cells is regulated by estrogen (E2) and its receptors (ER). PPT, ERa-
selective agonist, has showed to increase the proliferation of thyroid cancer cells, 
while DPN, ERp-selective agonist, decrease it. Therefore, ER a is positively 
associated with and is involved in thyroid cancer cell proliferation and in contrast, 
ER 13 negatively associated with the proliferation and is involved in the induction 
of apoptosis of thyroid cancer cells. 
On the other hand, there are increasing studies of PPARy and its involvement in 
several metabolic pathways, in adipocyte differentiation, and even in the growth 
inhibition of different cancer cells. Therefore, an increasing physiologic 
significance has been attributed to the crosstalk among nuclear receptors, which 
was observed at several levels of the signal transduction cascades. As mentioned 
previously about the interaction between PPAR and ER pathways, the PPAR/RXR 
heterodimer has been shown to bind to estrogen response element (ERE)—related 
palindromic sequences; however, it cannot transactivate due to a non-permissive 
natural promoter structure (Wang X et al., 2002). On the other hand, ERs 
negatively interfere with PPAR response element (PPRE)—mediated 
transcriptional activity; however, the molecular mechanisms involved still remain 
to be elucidated. Therefore, it is important to investigate the crosstalk among 
nuclear receptors and to explore whether there was a link between ER and PPAR 
7 in thyroid cancer cells. 
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1.7 Objectives of this project 
Peroxisome proliferator-activated receptor gamma (PPAR) is a member of the 
nuclear hormone receptor superfamily. PPARy is involved in cell cycle control 
and apoptosis in cancer cells, and the activation of PPAR plays an inhibitory role 
in cell proliferation and growth. Previous studies from our laboratory have shown 
that the proliferation of thyroid cancer cells is regulated by estrogen (E2) and its 
receptors (ER). ERa is positively associated with thyroid cell proliferation and in 
contrast, ERp negatively associated with the proliferation. Since both PPARy as 
well as ER play important roles in cell proliferation and apoptosis in thyroid 
cancer cells, the most important purpose of this project is to explore whether there 
was a link between ER and PPARy in thyroid cancer cells. 
29 
Chapter Two 
General Materials and Methods 
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Chapter Two General Materials and Methods 
2.1 Materials 
2.1.1 Cell lines 
Cell Lines Sources Supplier 
KAT-5 Human thyroid papillary Prof. George 
carcinoma cell line Chen, CUHK 
FRO Human thyroid follicular Prof. George 
carcinoma cell line Chen, CUHK 
NPA Human thyroid papillary Prof. George 
carcinoma cell line Chen, CUHK 
WRO Human thyroid follicular Prof. George 
carcinoma cell line Chen, CUHK 
ARO Human thyroid follicular Prof. George 
carcinoma cell line Chen, CUHK 
2.1.2 Plus mid vectors used in this study 
Vectors Manufacturers 
pFATP-(PPRE)3-tkLuc vector Prof Bart Staels, UR545INSERM, 
Departement d'Atherosclerose, Institut 
Pasteur Lille, 1 rue Calmette, 59019 
Lille, France. 
pGL3_basic vector Promega， 
pGL3_control vector Promega， 
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2.1.3 Antibodies 
Antibodies Manufacturers Cat no. 
Anti-p-Actin (JLA20) Calbiochem, San Diego, C A C P O l 
Anti-PPARy (E-8) Santa Cruz Biotechnology, sc-7273 
Santa Cruz, CA 
Anti-Goat Ig-HRP Santa Cruz Biotechnology, sc-2020 
Santa Cruz, CA 
Anti-Rabbit Ig-HRP Santa Cruz Biotechnology, sc-2005 
Santa Cruz, CA 
Anti-Mouse IgG-FITC Santa Cruz Biotechnology, sc-2970 
Santa Cruz, CA 
2.1.4 Culture media and transfection reagents 
Materials Manufacturers 
Penicillin GIBCO-BRL (Carlsbad, CA) 
Streptomycin GIBCO-BRL (Carlsbad, CA) 
Fetal bovine/calf serum (FBS) GIBCO-BRL (Carlsbad, CA) 
Phosphate Buffered Saline (PBS) Sigma (St. Louis, MO) 
LipofectAMINE Invitrogen (Carlsbad, CA) 
Trypsin-EDTA GIBCO-BRL (Carlsbad, CA) 
RPMI-1640 GIBCO-BRL (Carlsbad，CA) 
DMEM GIBCO-BRL (Carlsbad, CA) 
Dimethyl sulfoxide (DMSO) Sigma (St. Louis, MO) 
3-(4,5-dimethylthiazol-2-yl)-2,5- Sigma (St.Louis, MO) 
diphenyltetrazolium bromide, MTT 
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2.1.5 Materials for protein manipulation 
Materials Manufacturers 
Acrylamide/Bis-acrylamide Beohringer Mannheim (Mannheim, Germany) 
Sodium orhovanadate Sigma (St. Louis, MO) 
Aprotinie Sigma (St. Louis, MO) 
Dihiothreitol (DTT) Sigma (St. Louis, MO) 
Polyvinylidene difluoride membrane Amersham Biosciences 
(PVDF membrane) (Buckinghamshire, UK) 
Phenylmethylsulfonyl fluoride Sigma (St. Louis, MO) 
(PMSF) 
Sodium deoxycholate Sigma (St.Louis,MO) 
Dithiothreitol USB Cooperation 
(Cleveland,Ohio) 
bromophenol blue Bio-Rad (Hercules,CA) 
Glycerol Sigma (St.Louis,MO) 
Sodium dodecyl sulfate (SDS) USB Cooperation 
(Cleveland, Ohio) 




Tris-HCl “ USB Cooperation 
(Cleveland, Ohio) 
NaCl “ USB(Cleveland,Ohio) 
Tween-20 “ USB(Cleveland,Ohio) 
ECL Western Blotting detection Amersham Biosciences 
(Buckinghamshire, UK) 
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X-ray film Amersham Biosciences 
(Buckinghamshire, UK) 
Proteins molecular weight marker full Amersham Biosciences 
range rainbow marker (Buckinghamshire, UK) 
Paraformaldehyde Sigma(St.Louis,MO) 
Triton USB(Cleveland,Ohio) 
Bovine serum albumin, BSA Sigma(St丄ouis，MO) 
2.1.6 Drugs for treatment 
Materials Manufacturers 
Propyl pyrazole troil (PPT) Sigma (St. Louis, MO) 
Diarylpropionitrile (DPN) Tocris 
Genistein Sigma (St. Louis, MO) 
Mifepristone (RU486) Sigma (St. Louis, MO) 




Luciferase Assay System Promega (Madison, WI) 
Protein DC assay Bio-Rad (Hercules, CA) 
ECL Western blot detection kit Amersham Biosciences 
(Bucking Hamshire, UK) 
Cell Death Detection ELISAplus Roche Applied Science (Germany) 
15(S)-HETE Enzyme Immunoassay Kit Assay Designs (USA) 
15d-PGJ2 Enzyme Immunoassay Kit Assay Designs (USA) 
13(S)-H0DE Enzyme Immunoassay Kit Assay Designs (USA) 
2.1.8 Instruments 
Materials Manufacturers 
Centrifuge Eppendorf (Hamburg, Germany) 
UV-spectrophotometer Beckman, Fullerton, CA 
Olympus BH-2 microscope Olympus (Tokyo, Japan) 
Mini Trans-Blot Electrophoretic Transfert Bio-Rad (Hercules, CA) 
cell 
Nikon OPTIPHOT-2 fluorescence Nikon (Tokyo, Japan) 
microscope 
Mini orbital shaker S05 Stuart Scientific(Staffordshire,UK) 
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2.2 Methods 
2.2.1 Cell Culture 
FRO, WRO and ARO, human thyroid papillary carcinoma cell lines and NPA, 
human thyroid follicular carcinoma cell line, were maintained in RPMI-1640 
medium supplemented with 10% FBS, lOOU/mL penicillin and lOOg/mL 
streptomycin at 37°C with 5% C02/95% air. The culture medium was changed 
twice a week. 
2.2.2 Cell viability analysis 
MTT [3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay was 
first described by Mosmami in 1983 (Mosmann, 1983)，is based on the ability of a 
mitochondrial dehydrogenase enzyme from viable cells to cleave the tetrazolium 
rings of the pale yellow MTT and form a dark blue formazan crystals which is 
largely impermeable to cell membranes, thus resulting in its accumulation within 
healthy cells. Solubilization of the cells by the addition of a detergent results in 
the liberation of the crystals which are solubilized. The production of the dark 
blue crystal formazan in cells treated with an agent is measured relative to the 
production in control cells, and a dose-response curve can be generated through a 
spectrophotometer. Cells were seeded at the initial density of 10^^/200|j,l/well in 
96-well microtitration plates (Becton Dickson Labware, Franklin Lakes, NJ). 24 
hours after plating, cells were incubated with various concentrations of PPT and 
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DPN for different time points. After treatment, aspirating the medium, 200|il 3-
(4,5-dimethylthiazol-2 yl)-2,5-diphenyl-2H-tetrazolium bromide solution diluted 
with RPMI-1640 medium (MTT, 5 mg/ml in RPMI-1640) was then added in each 
well and incubated for 4 hours at 37°C to allow MTT metabolized. The medium 
was aspired and the formazan crystals were dissolved by adding lOOjil/well 
dimethylsulphoxide (DMSO). The absorbance at 570 nm was measured using a 
reference wavelength of 630 nm with a microplate reader. Cell Viability was 
presented as percentage of control culture conditions. 
2.2.3 Preparation of protein extract 
Cells (lO?) were trypsinized from the culture dish and washed twice with icecold 
PBS, then lysed in 250|il of radioimmunoprecipitation buffer (RIPA buffer: IX 
PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, pH7.6) together 
with the protein inhibitor 1 |Lig/ml aprotonin and 100|ig/ml phenylmethy-
sulphonyl-fluoride (PMSF). The cells were further disrupted and homogenized by 
passage through 21 gauge needles and incubated at 4°C for 45 minutes. After 
centrifugation at 10000 rpm for 10 minutes at 4°C, the supernatant (total protein) 
was recovered and frozen at -20°C. 
2.2.4 Determination of the concentration of target protein 
Protein concentration was determined by the Bio-Rad Protein Assay (Bio-Rad, 
Hercules, CA). The standard was constituted by diluted bovine serum albumin 
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(BSA in REP A buffer, 0 - 1.4|ig/ml). The assay was performed in 96-well plate 
(Becton Dickson Labware, Franklin Lakes, NJ) 5|il of standards and sample 
proteins were added into the well. After pretreated were pretreated with 25|il 
Reagnet A', both the standards and sample proteins were added with 200|j.l Dye 
reagent. After incubation for 15 minutes in room temperature, the concentration 
was determined with a spectrophotometer (Beckman Instruments, Inc., Fullerton, 
CA) atX = 595nm. 
2.2.5 Gel electrophoresis and protein transfer 
An aliquot of a protein sample (50}j.g) was mixed with 6x SDS loading buffer 
(50mM Tris-HCl pH6.8，lOOmM dithiothreitol, 2% SDS, 0.1% bromophenol blue, 
10% glycerol). The protein sample was then denatured by heating at 99°C for 5 
minutes. 30|ig of total protein per lane were resolved on a 10-15% sulphate-
polyacrylamide gel (SDS-PAGE). Electrophoresis was carried out at room 
temperature at lOOV for 3-4 hours. The gels were calibrated with broad range 
markers (Bio-Rad, Hercules, CA). After electrophoresis, the gel was equilibrated 
at room temperature for 10 minutes in transfer buffer (25mM Tris, 192mM 
Glycine, 20% methanol, pH8.3). The proteins were transferred onto a PVDF 
membrane (Millipore Inc., Bedford, MA) using a Bio-Rad Mini Trans-Blot cell. 
The transfer sandwich was assembled with sponge on the bottom half of plastic 
cassette, followed by a filter paper, stacking gel, PVDF membrane(Millipore Inc., 
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Bedford, MA), filter paper and sponge. The transfer was performed for 90 
minutes at lOOV at room temperature. Cooling was supplied by surrounding the 
transfer tank with ice and circulating the Iransfer buffer with stirrer bar. After the 
transfer, the membrane (filter) with proteins would be ready for immunoblotting. 
2.2.6 Immunoblotting 
Protein filters were incubated for 1 hour at room temperature in a blocking 
solution consisting of 5% non-fat milk in TEST (lOmM Tris-HCl, pH 7.5, 
lOOmM NaCl, 0.1% Tween-20), then incubated with diluted primary antibodies 
at 4°C, overnight. After washing with TBST for three times, the membrane was 
incubated with corresponding diluted secondary antibodies for one hour, at room 
temperature. Following the TBST washing, ECL reagent kit (Amersham Life 
Science Ltd., Buckinghamshire, UK) was added on the membrane and exposed to 
x-ray films from 10 seconds to 5 minutes. 
The primary antibodies was diluted in TBST while the secondary antibody was 
diluted in 2% non-fat milk in TBST, the diluted rates of all primary antibodies 
and secondary antibodies used in immunoblotting were described in Table 1.1. 
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Table 1.1 Diluted rates of primary and secondary antibodies used in 
immunoblotting 
Primary antibodies Manufacturers Dilution 
Anti-P-Actin (JLA20) Calbiochem, San Diego, 1:500 
CA 
Anti-PPARy (E-8) Santa Cruz Biotechnology, 1:1000 
Santa Cruz, CA 
Secondary Antibodies Manufacturers Dilution 
Anti-Rabbit Ig-HRP Santa Cruz Bio technology ,1 :2000 
Santa Cruz, CA 
Anti-Goat Ig-HRP Santa Cruz Biotechnology, 1:2000 
Santa Cruz, CA 
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2.2.7 Apoptosis detected by Cell Death Detection ELISAplus 
Cell Death Detection ELISAplus was used to detect apoptosis induced by PPT 
and DPN. It is known that apoptosis is distinguished from necrosis or accidental 
cell death by characteristic morphological and biochemical changes, including 
compacting and fragmentation of the nuclear chromatin, shrinkage of the 
cytoplasm and loss of membrane asymmetry (Eamshaw, 1995). During apoptosis, 
various endonucleases are activated which cleave the chromatin into nucleosome-
sized fragments of 180bp and multiples thereof, generating the typical "ladder" 
pattern observed with agarose gel electrophoresis (Cummings MC et a l , 1997). 
Nuclesomes are elementary units of chromatin formed by an octamer of histones 
and 146bp DNA wrapped around it. The nucleosomes are connected by linker 
DNA of about 15-lOObp which are the preferential binding sites of the 
endonucleases. Under physiological conditions, nucleosomes are packed into 
apoptotic bodies and phagocytized by macrophages or neighboring cells. In 
situations of enhanced cell death these mechanisms are overloaded and 
nucleosomes are also released into circulation (Jahn S. et al., 2001). 
Quantification of these circulating nucleosomes can be used to estimating the 
extent of cell death. 
The Cell Death Detection ELISAplus is based on a quantitative sandwich-
enzyme-immunoassay principle: Monoclonal mouse antibodies directed against 
DNA and histones detect specifically mono-and oligonucleosomes. (Figure 2.1). 
The sample was placed in a streptavidin-coated microliter plate and incubated 
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with a mixture of biotinylated anti-histone antibodies, peroxidase-labeled anti-
DNA antibodies and incubation buffer (1% BSA，0.5% Tween, ImM EDTA in 
PBS) for two hours. The antibodies were bound to the histone- and DNA-
component of the nucleosomes, and the immunocomplexes were fixed to 
themicrotiter plate by streptavidin-biotin interaction. After the incubation period, 
unbound antibodies were removed by a washing step. The peroxidase-linked 
complexes retained were incubated with ABTS for 30 minutes, resulting in color 
development proportional to the number of nucleosomes captured in the antibody 
sandwich. Quantification of the nucleosomes was performed by photometrical 
determination of the absorbance at 405nm against substrate solution as blank 
(reference wavelength at 492nm). 
In this project, cells were seeded at 10^^/200|il/well in a 96-well plate (Becton 
Dickson Labware, Franklin Lakes, NJ) and incubated overnight to allow cells to 
attach to the plate. Cells were then exposed with various concentrations of PPT 
and DPN (OuM, O.luM, 0.5uM, luM, 5uM and lOuM) for 48hours. After the 
incubation, the cells were pelleted by centrifugation (200 x g for 10 minutes) and 
the supernatant, which contained DNA from necrotic cells that leaked through the 
membrane during incubation, is discarded. Then, cells were resuspended and 
incubated in lysis buffer for 10 minutes. After lysis, intact nuclei were pelleted by 
centrifugation. lOOuL of the supernatant were transferred to a streptavidin-coated 
well of a microplate and incubated for 2 hours to allow the binding of 
nucleosomes in the supernatant with two monoclonal antibodies, anti-histone 
(biotin-labeled) and anti-DNA(peroxidase-conjugated). Antibody-nucleosome 
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complexes were then bound to the streptavidin. Samples were then washed with 
incubation buffer three times to allow the removal of the components that are not 
immunoactive. Finally, samples were incubated with peroxidase substrate (ABTS) 
for 15 minutes and absorbance were measured at 405nm. 
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Figure 2.1 Principles of the Cell Death Detection ELISA plus assay. 
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2.2.8 PPARy-ligands Enzyme Immunoassay 
2.2.8.1 15d-PGJ2 Enzyme immunoassay 
15d-PGJ2 Enzyme immunoassay kit is an immunoassay for the quantitative 
determination of 15-deoxy-A 12,14-Prostaglandin J2 (15-d-PGJ2) in biological 
fluids. The kit uses a polyclonal antibody to 15-d-PGJ2 to bind, in a competitive 
manner, the l5-d-PGJ2 in the sample covalently attached to it. After a 
simultaneous incubation the excess reagents are washed away and substrate is 
added. After a short incubation time the enzyme reaction is stopped and the 
yellow color generated read on a microplate reader at 405nm. The intensity of the 
bound yellow color is inversely proportional to the concentration of 15-d-PGJ2 in 
either standards or samples. The measured optical density is used to calculate the 
concentration of 15-d-PGJ2. 
In this project, cells were seeded at 10'^/200|il/well in a 96-well plate (Becton 
Dickson Labware, Franklin Lakes, NJ) and incubated overnight to allow cells to 
attach to the plate. Cells were then exposed with various concentrations of PPT 
and DPN (OuM, 0.1 uM, 0.5uM，luM, 5uM and lOuM) for 48hours. Kits were 
used following the original manuals and the measurements were performed in 
duplicates. 
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2.2.8.2 15(S)-HETE Enzyme immunoassay 
15(S)-Hydroxyeicosatetraenoic acid [15(S)-HETE] kit is an immunoassay for the 
quantitative determination of 15(S)-HETE in biological fluids. The kit uses a 
polyclonal antibody to 15(S)-HETE to bind, in a competitive manner, the 15(S)-
HETE in the standard or sample covalently attached to it. After a simultaneous 
incubation at room temperature the excess reagents are washed away and 
substrate is added. After a short incubation time the enzyme reaction is stopped 
and the yellow color generated is read on a microplate reader at 405nm. The 
intensity of the bound yellow color is inversely proportional to the concentration 
of 15(S)-HETE in either standards or samples. The measured optical density is 
used to calculate the concentration of 15(S)-HETE. 
In this project, cells were seeded at 10'^ /200|Lil/well in a 96-well plate (Becton 
Dickson Labware, Franklin Lakes, NJ) and incubated overnight to allow cells to 
attach to the plate. Cells were then exposed with various concentrations of PPT 
and DPN (OuM, 0.1 uM, 0.5uM, luM, 5uM and lOuM) for 48hours. Kits were 
used following the original manuals and the measurements were performed in 
duplicates. 
2.2.8.3 13(S)-HODE Enzyme immunoassay 
13-hydroxyoctadecadienoic acid [13(S)-H0DE] Enzyme Immunoassay (EIA) kit 
is an immunoassay for the quantitative determination of free 13(S)-H0DE in 
46 
biological fluids. The kit uses a polyclonal antibody to 13(S)-H0DE to bind, in a 
competitive manner, the 13(S)-H0DE in the sample covalently attached to it. 
After a simultaneous incubation at room temperature the excess reagents are 
washed away and substrate is added. After another incubation, the enzyme 
reaction is stopped and the yellow color generated read on a microplate reader at 
405 nm. The intensity of the bound yellow color is inversely proportional to the 
concentration of 13(S)-H0DE in either standards or samples. The measured 
optical density is used to calculate the concentration of 13(S)-H0DE. 
In this project, cells were seeded at 10^^/200|j.l/well in a 96-well plate (Becton 
Dickson Labware, Franklin Lakes, NJ) and incubated overnight to allow cells to 
attach to the plate. Cells were then exposed with various concentrations of PPT 
and DPN (OuM, 0.1 uM, 0.5uM, luM, 5uM and lOuM) for 48hours. Kits were 
used following the original manuals and the measurements were performed in 
duplicates. 
2.2.9 Transient transfection and luciferase activity assay 
Genetic reporters are used commonly in studying gene expression and other 
cellular events coupled to gene expression, such as functional analysis of 
promoter, receptor activity, intracellular signal transduction, mRNA processing, 
protein folding and protein-protein interactions (Alam, and Cook, 1990). Firefly 
luciferase is widely used as reporter because of its immediate availability upon 
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translation, its high sensitivity and its easiness and rapidity when performance 
(Wood, 1990). 
H O v ^ S v ^ ^ ^ y ^ y C O O H FitdiyLucifeme 一 O V V ^ W ^ 。 聽 
,ATP•。公 ~ — ^ k J V ^ s � •令 p r i ， o v _ 
Beetle L iicikriii Oxvl ucHertn 
Figure 2.4 Biolummesceut reaction catalyzed by firefly ludferase 
Three of the Luciferase Reporter Vectors (Promega, Madison, WI) 一pGL3-basic 
(Figure 2.2)，pGL3-control (Figure 2.3) and pFATP-(PPRE)3-tkLuc (FATP-
derived PPARy response element with firely luciferase gene under the control of a 
thymidine kinase promoter were used in this project to provide a basis for the 
quantitative analysis of functional analysis in promoter. The pGL3 Luciferase 
Reporter Vectors contain the cDNA encoding luciferase (/wc+) cloned from the 
North American firefly {Photinus pyralis) and a vector backbone that has been 
designed to provide enhanced reporter gene expression. pGL3-Basic vector, 
lacking eukaryotic promoter and enhancer sequences, was applied as negative 
control to measure the background of firefly luciferase expression while pGL3-
control vector containing SV40 promoter and enhancer sequences were used as 
positive control. 
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To perform the luciferase assay, the cells were first transfected with the above vector 
or plasmids. Transient transfection was performed using Lipofectamine reagent 
(Invitrogen, Carlsbad, CA), according to the protocol recommended by the 
manufacturer. Cells were seeded in 12-well plates at a density of 1 x lO^cells/well 
and allowed to reach 60-70% confluence. The cells were transiently transfected 
with Lipofectamine (Invitrogene, Carlshad, CA) at a Lipofectamine/DNA ratio of 
3:1 in the absence of serum with 1 |ig/well of either the PPAR-Y-responsive 
reporter plasmid pFATP- (PPRE)3-tkLuc (FATP-derived PPAR Y response 
element with firefly luciferase gene under the control of a thymidine kinase 
promoter) or pGL3 basic vector or pGL3-control vector. After 6 h of transfection, 
cells transfected with pFATP- (PPRE)3-tkLuc were washed and treated with 
various concentrations of PPT and DPN (OuM, O.luM，0.5uM, luM，5uM and 
lOuM) for 48hours in the presence of serum. After 48 h, cells were lysed and the 
luciferase activity was assayed in the lysates. 
Luciferase assays were performed according to the users' manual of luciferase 
assay stsytem (Promega, Madison, WI). After washing the cells with PBS twice, 
200^1 lyasis buffer was added into each well and the cells were extracted from the 
plate by a scraper. The lysis solution was then transferred into a microcentrifuge 
tube and incubated on ice. After centrifuging at 14000rpm for 2 minutes (4oC), 
the supematants were aspirated to a new tube. 20|il cell lysate together with 65|il 
of Luciferase assay reagent was added into a well in a 96-well plate. The light 
intensity of each well was measure by a luminometer (Molecular Derices, 
Fullerton, CA). All experiments were performed at least three times in each 
plasmid. 
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Figure 2.2 Circle Map of pGL3-Basic Vector. 
/MC+, C D N A encoding the modified firefly luciferase; Ampr, gene conferring 
ampicillin resistance in E. coli\ f l ori, origin of replication derived from 
filamentous phage; ori, origin of replication in E. coli. Arrows within luc+ and 
the Ampr gene indicate the direction of transcription; the arrow in the fl ori 
indicates the direction of ssDNA strand synthesis. 
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Figure 2.3 Circle map of pGL3-Control Vector. 
luc+, cDNA encoding the modified firefly luciferase; Ampr, gene conferring 
ampicillin resistance in E. coli; f l ori, origin of replication derived from 
filamentous phage; ori, origin of replication in E. coli. Arrows within luc+ and 
the Ampr gene indicate the direction of transcription; the arrow in the f l ori 
indicates the direction of ssDNA strand synthesis. 
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2.2.10 Statistical Analysis 
The data were presented as mean for at least three separate determinations 
for each group. Differences between groups were examined for statistical 
significance using Student's t-test or one-way ANOVA followed by Student's t-
test. P<0.05 was used to indicate a statistically significant difference. 
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Chapter Three 
Estrogen Receptor-a (ERa) and Estrogen Receptor-
P(ERP) mediate the proliferation and apoptosis of 
human thyroid papillary carcinoma cells 
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3.1 Introduction 
Thyroid cancer is the most common malignancy of the endocrine system, and 
papillary carcinoma is the most common type of thyroid malignancy, accounting 
for 65-80% of all thyroid cancers (Schlumberger MJ et al, 1998). It represents 
most of the thyroid cancers that occur in children and young adults, whether 
idiopathic or radiation. A small proportion is familial. However, there is 
increasing evidences to suggest that tumorigenesis in certain organs and tissues is 
influenced by endocrine function and hormones, particularly estrogen (Manole et 
al.,2001) 
Estrogen, acting through estrogen receptor alpha (ERa) and beta (ERp), play an 
important role in carcinogenesis. Both receptors bind estrogen (E2) with the same 
affinity, but they can activate certain promoters differentially and on some 
promoters ERp can behave as a negative modulator of ERa activity. (Saville et a l , 
2000). In breast cancer cells, about 2/3 of it express ERa and 70% of these 
respond to the antiestrogen tamoxifen (Clarke et. al., 1996). At some of the 
promoters, tamoxifen is an agonist in the presence of ERp and it is possible that 
ERp involves an antiproliferative, proapoptotic role during tamoxifen therapy 
(Iwao et al., 2001). In recent years, much effort has been invested in the 
development of ERa- and ERP-agonists and antagonists. Several such 
compounds have been developed, and this has permitted dissection of the specific 
functions of each receptor. One ERa-specific agonist, PPT, is 410-fold more 
potent in binding to ERa than ERp (Stauffer et al., 2000). 
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Our previous study demonstrated that both estrogen receptors (ER) a and estrogen 
receptor (ER) P existed in KAT-5 cells and that E2 was able to promote the 
proliferation of KAT-5 cells (Cell Proliferation, Inpress.). In addition, both ERa 
and ERp play an important role in the proliferation and growth of thyroid cancer 
cells as their roles are determined using various ER agonists and ER antagonists. 
Several such compounds have been developed, one of the ERa-specific agonists, 
4,4',4"-(4-propyl(lH)-pyrazole-l,3,5-triyl)trisphenol (PPT), has been shown to 
stimulate proliferation and its binding affinity is 410-fold more potent in binding 
to ERa than ERp (Stauffer et a l , 2000). In the other hand, one of the ERp-
agonists, 2.3-bis(4-hydroxy-phenyl)-propionitrile (DPN) has been shown to 
inhibited cell growth and induced apoptosis, it binds to ERP with an affinity 72-
hold higher than to ERa (Meyers et al., 2001). As ERa and ERP have opposing 
cellular responses and both ERa and ERp are functional, the tendency for cells to 
promote proliferation or to induce apoptosis is dependent on the binding affinity 
of ERa and ERp. According to the study of Heiguero et al., it showed that PPT 
caused an increase in cell number of nearly 50% while DPN caused a decrease of 
30% compared to the untreated cells (Heiguero et al. 2005). Both PPT and DPN 
had positive effects on cell metabolism, however, activation of ERa is 
independent of ERp, and vice versa. We observed that PPT promoted cell 
proliferation whereas DPN suppressed it. Therefore，it raises that ERa and ERP 
may have opposite functions in the regulation of thyroid cell proliferation. The 
mechanism responsible for the inhibitory effect of DPN and ERp on cell 
proliferation appears to be associated with the ability of DPN to induce apoptosis. 
However, the differential functions of ERa and ERp have not been previously 
reported in thyroid cells. Also, the molecular pathways of ERa and ER(3 have not 
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been well-defined, especially in thyroid carcinoma cells. Therefore, in order to go 
further and deeper about the opposing role of cell proliferation in thyroid cancer, 
it is necessary to confirm that both ERa and ERp are exist in thyroid cancer cells 
and the effect when treating with ERa-selective agonist PPT and ERP-selective 
agonist DPN. 
3.2 Materials and Methods 
3.2.1 Cell culture and treatment 
NPA, a human papillary thyroid carcinoma cell line, WRO and FRO, human 
follicular thyroid carcinoma cell lines, were maintained in RPMI1640 medium 
supplemented with 10% FBS, lOOU/mL penicillin and lOOg/mL streptomycin at 
37°C with 50/0CO2/950/0 air. At 70-80% confluence, the medium was changed to 
phenol red-free RPMI1640 medium before treating with PPT and DPN for 48hrs. 
3.2.2 Western Blot 
The procedure of Western blotting has been described in Chapter 2. 30fig of 
sample proteins were electrotransfered to nitrocellulose membranes and blocked 
in PBS, 0.1% Tween, containing 5% nonfat dried milk at room temperature for 1 
hour. Blots were incubated overnight at 4°C with primary antibody in PBS with 
0.1% Tween: anti-ERa (1:1000), anti-ERp (1:1000), anti-PPARy (1:1000) or P-
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actin (1:1000) and then incubated with the corresponding secondary antibody in 
PBS with 0.1 % Tween, containing 5% nonfat dried milk. Immunoreactive 
proteins were detected with the enhanced chemiluminescence (ECL) Western 
blotting detection system. Anti-a-Tubulin (1:2000) or Anti-P-Actin (1:10000) was 
used to control protein loading. 
3.2.3 Cell proliferation determined by MTT assay 
Cytotoxicity assay, MTT, was carried out according to the procedures described 
in Chapter 2. In brief, cells were seeded at the initial density of 104/200|al/well in 
96-well microtitration plates. 24 hours after plating, cells were incubated with 
different concentrations of PPT (0, 0.1，0.5, 1，5，10|iM) for 24hr, 48 hr and 72hr. 
After aspirating the medium, 200|il 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide solution diluted with RPMI 1640 medium (MTT, 5 
mg/ml in RPMI1640) was then added in each well and incubated for 4 hours at 
37oC to allow MTT metabolized. The medium was aspired and the formazan 
crystals were dissolved by adding lOOfil/well dimethylsulphoxide (DMSO). The 
absorbance at 570 nm was measured using a reference wavelength of 630 nm with 
a microplate reader. Cell viability was presented as percentage of control culture 
conditions. 
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3.2.4 Apoptosis detected by Cell Death ELISAplus assay 
The Cell Death ELISAplus kit (Roche) was used to detect apoptosis that was 
induced by PPT and DPN. NPA cells were seeded at lO* cells/200|iL in 96-well 
plates and incubated overnight to allow cells to attach to the plate. The cells were 
treated with PPT (0|iM, 0.1 |aM, 0.5|iM, l|iM, 5|iM, 1 0 _ and DPN (OnM, 
0.1 jiM, 0.5|aM, l|iM, 5ijM, lOpM) for 48 hours. After the incubation, cells were 
pelleted by centrifugation. Cells then were lysed and intact nuclei were pelleted 
by centrifugation and 100|iL of the supernatant were used for detection of the 
amount of apoptotic cells by transferring to the streptavidin-coated microplate 
(provided by the kit). To quantify the apoptotic cells by following the protocol 
provided by the Kit ('http://www.roche-applied-science.com). In summary, the 
Cell Death Detection ELISAplus is based on a quantitative sandwich-enzyme-
immunoassay principle: Monoclonal mouse antibodies directed against DNA and 
histories detect specifically mono-and oligonucleosomes. (Figure 2.1). The sample 
was placed in a streptavidin-coated microtiter plate and incubated with a mixture 
of biotinylated anti-histone antibodies, peroxidase-labeled anti-DNA antibodies 
and incubation buffer (1% BSA, 0.5% Tween, ImM EDTA in PBS) for two hours. 
The antibodies were bound to the histone- and DNA-component of the 
nucleosomes, and the immunocomplexes were fixed to themicrotiter plate by 
streptavidin-biotin interaction. After the incubation period, unbound antibodies 
were removed by a washing step. The peroxidase-linked complexes retained were 
incubated with ABTS for 30 minutes, resulting in color development proportional 
to the number of nucleosomes captured in the antibody sandwich. Quantification 
of the nucleosomes was performed by photometrical determination of the 
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absorbance at 405mn against substrate solution as blank (reference wavelength at 
492nm). The enrichment factor is calculated by comparing the apoptotic cells 
when treated with PPT or DPN with the apoptotic cells with no treatment. 
3.3 Results 
3.3.1 The expression of ERa, ERP and PPARy in NPA’ FRO, ARO and WRO 
thyoid cancer cell lines 
Since ERa, ERp and PPARy were known to be important nuclear receptors in the 
regulation of various cancer cells, we first determined whether the expression of 
the three nuclear hormone receptors were expressed in the thyroid carcinoma cell 
lines. ERa, ERp and PPARy protein expression were measured by Western blot 
in four thyroid cancer cell lines. The four thyroid carcinoma cell lines chosen to 
examine the expression of and PPARy were: NPA, human thyroid papillary 
thyroid carcinoma cell line; FRO, WRO, ARO, human thyroid follicular 
carcinoma cell lines. PPARy protein was identified at the expected molecular 
mass of 54kDa in all cell lines (shown in Figure 3.1). Also, the other two nuclear 
receptors, ERa and ERp, were also expressed at the expected molecular mass of 
67kDa and 58kDa, respectively. From this experiment, it confirmed that the ERa, 
ERp and PPARy were expressed in all cell lines. 
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Protein expression from cell lines 
NPA FRO ARO WRO 
PPARy 
Figure 3.1 Expression of ERa, ERP and PPARy in thyroid cell lines NPA, FRO, 
ARO and WRO. Total proteins from NPA, FRO, ARO and WRO cell lines were 
extracted and Western blot was performed to determine the expression of ERa, 
ERp and PPARy. p-tubulin was used as protein for standardization. 
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3.3.2 Effects of PPT and DPN on cell viability 
The experiment above had shown that the four human thyroid carcinoma cell lines 
NPA, FRO, WRO and ARO express ERa, ERp and PPARy. It provided a good 
model with which to investigate further the effect of ERa-selective agonist PPT 
and ER(3-selective agonist DPN on the growth of thyroid cancer cells. Although 
four thyroid cancer cell lines expressed ERa, ERp and PPARy, NPA had been 
chosen for the further investigation. The effect of two drugs: PPT, ERa-selective 
agonist, and DPN, ERp-selective agonist, on cell viability were assessed by MTT 
assay. Treatments with both compounds were carried out in NPA cell line. In this 
study, we first examined the cell viability of NPA treated with PPT (0|iM, 0.1 ^ iM, 
l|iM, 5\iM, 10|iM, 20|iM) and DPN (O i^M, O.l^ iM，l|iM, lOfiM，20^M) for 
24hr, 48hr and 72hr by MTT assay. 
According to the result of MTT assay, ERa-selective agonist PPT at the 
concentration of lO'^M promoted cell proliferation at around 20% for 24hr, 48hr 
and 72hr (Figure 3.2), the maximal effect of PPT was achieved at 48hr after 
treatment. In addition, when cells treated with PPT with concentrations higher 
than lO'^M, the cell proliferation dropped gradually at all three time-points 24hr, 
48hr and 72hr. 
When NPA cells were treated with DPN, an ERP-selective agonist, cell viability 
was reduced to around 20% in cells at 24hr, 48hr and 72hr after the treatment with 
l^M, lOjiM and 20^M. 
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Figure 3.2 Cell proliferation determined by MTT assay in NPA cells treated 
with PPT (0，0.1 fiM, S^M, lOfiM, 20fiM). Compared to the untreated cells (as 
control), there was a significant increase in cells at 24hr, 48hr and 72hr of 
treatment with IfxM (10'^ M) of PPT (*P<0.05), Data were the mean 土 S.D. of 4 
separate experiments. 
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Figure 3.3 Cell proliferation determined by MTT assay in NPA cells treated 
with DPN (0，0.1 fiM, 5juM, lOfiM，20_. Compared to the untreated cells (as 
control), there was a significant increase in cells at 24hr, 48hr and 72hr of 
treatment with IjuM (10'^ M) of DPN (*P<0.05). Data were the mean 土 S.D. of 4 
separate experiments. 
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3.3.3. Apoptotic cells quantification by Cell Death ELISAplus assay 
After measuring the cell viability of NPA cells with the ERa-selective agonist 
PPT and ERp-selective agonist DPN, which showed that ERa-agonist PPT 
enhanced the proliferation of NPA cells while the ER(3-agonist DPN inhibited the 
cell proliferation, quantification of apoptotic cells by using Cell Death Detection 
ELISAplus kit had been tested in order to differentiating apoptotic cells from 
necrotic cells. The Cell Death Detection ELISAplus was used to quantify DNA 
fragmentation in apoptotic cells, based on the detection of mono- and 
oligonucleosomes in the cytoplasmic fractions of cell lysates as mentioned in 
Chapter two. According to the previous result from the MTT experiment, it 
showed that the optimal effect was achieved when cells treated for 48hrs. 
Therefore, treatment of PPT and DPN for 48 lir had been used for the detection of 
the apoptotic cells. 
From the apoptotic analysis shown in Figure 3.4，NPA cells were treated with 
PPT at concentrations of 0|iM, 0.1 |iM, 0.5|iM, l|iM, 5\M and 10|iM for 48 hr. 
When compared to the untreated cells (as control), it showed that there was a 
significant decrease in survival cells at 48 hr after the treatments with 0.1 |iM, 
0.5|iM, l|iM, 5\iM and 10|iM of PPT. From the apoptotic analysis shown in 
Figure 3.5, it showed that treatment of DPN for 48 hr resulted in a significant 
increase in apoptotic rates in NPA cells. 
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Figure 3.4 Apoptotic cell quantification determined by Cell Death ELISAplus 
assay in NPA cells treated with PPT (0，O.lfiM，O.SfiM, IfiM’ 5fiM, lO^M). 
Compared to the untreated cells (as control), there was a significant decrease in 
cells at 48hr of treatment with 0.1 fiM, 0.5/nM, IfM 5juM and lO^M of PPT 
(林P<0.01). Data were the mean 土 S.D. of 4 separate experiments. 
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Figure 3.5 Apoptotic cell quantification determined by Cell Death ELISAplus 
assay in NPA cells treated with PPT (0，O.luM, O.SfiM, IfiM, 5fiM，10_. 
Compared to the untreated cells (as control), there was a significant increase in 
cells at 48hr of treatment with 0.1 JUM, 0.5/LIM, IPIM, 5jLiM and LOFIM of DPN 
(叩<0.01). Data were the mean 土 S.D. of 4 separate experiments. 
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Combined with previous result, it indicated that PPT, the ERa-selective agonist, 
enhanced the proliferation of thyroid cancer cells and thus reduced the apoptosis. 
Unlike ERa, DPN, the ERp-selective agonist, inhibited the cell proliferation and 
promoted the apoptosis. 
3.4 Discussion 
There are increasing studies these years that suggest that tumorigenesis in certain 
organs and tissues is influenced by endocrine function and hormones, particularly 
estrogen. Estrogen plays an important role in the regulation of cancer cells. In 
other words, it is important to explore the role of ERa and ERp in the 
proliferation, growth and apoptosis of thyroid cancer cells. In this chapter, we 
continued to explore the roles of ERa and ERp in the proliferation and growth of 
thyroid cancer cells by employing various concentrations of ERa agonist and ERp 
agonist. 
To investigate whether the ERa, ERp and PPARy were involved in thyroid 
carcinogenesis, we analyzed the ERa, ERP and PPARy protein expression in 
several human thyroid carcinoma cell lines: NPA, FRO, WRO and ARO. The 
results indicated that ERa, ERp and PPARy were expressed in human thyroid cell 
lines NPA, FRO, WRO and ARO. Next, we would like to investigate the 
proliferation rate of thyroid cancer cells when they were treated with PPT, ERa-
selective agonist and DPN, ERp-selective agonist. 
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As shown in figure 3.2, upon exposure of the cells to PPT, ERa-selective agonist， 
there was an increase in cell number of nearly 20% compared to the untreated 
cells, suggesting that it promoted the proliferation and growth of NPA cells. It 
showed that the maximal proliferation rate was at the concentration of l^iM in 
24hr, 48 and 72hr, which provided us an optimal concentration of PPT treatment 
in further experiments. In figure 3.3，when exposing NPA cells to DPN, ERp-
selective agonist, it caused a decrease of around 25-30% compared to the 
untreated cells, suggesting that it inhibited the growth of NPA cell. It showed that 
there was a significant decrease in the inhibition of cell proliferation rate starting 
at concentration of l |iM of DPN. This result rise the possibility that ERa and ERp 
might have opposite functions in the regulation of thyroid cell proliferation. 
Furthermore, in order to investigate whether the altered cell proliferation caused 
by PPT and DPN was due to a change in apoptosis or necrosis, cell death was 
examined by Cell Death Detection ELISA, which could be used to differentiate 
the apoptosis from necrosis. The result indicated that the inhibitory effect on cell 
growth by DPN was due to the increase of the cells undergoing apoptosis and the 
promoting effect on cell growth by PPT was resulted from the decrease of 
apoptotic cells. 
In this apoptotic assay study shown in figure 3.4，cells treated with PPT, the ERa-
agonist, had showed a significant decrease in apoptosis when compared to control. 
When NPA cells treated with DPN, ERP agonist, it caused a significant increase 
in apoptotic cell amounts. Therefore, we suggested that PPT enhances the 
proliferation of NPA cells and thus reduced the apoptosis. Unlike ERa-agonist 
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PPT, DPN, the ERp agonist, inhibited cell proliferation and promoted the 
apoptosis. 
Several studies had suggested that estrogen receptors ERa and ERp may regulate 
apoptotic pathways in cancers. In our study, we proposed that the effect of ERa 
was involved in both cell proliferation promotion and apoptosis inhibition. In 
contrast, the effect of ERp was involved in the cell proliferation inhibition and 
apoptosis promotion. However, the molecular mechanisms underlying the 
opposing actions of ERa and ERp were still not clearly understood. 
During recent years, an increasing physiological significance had been attribute to 
the crosstalk among nuclear receptors. One example was the interaction between 
ER and PPAR pathways, the PPAR/RXR heterdimer had been shown to bind to 
estrogen response element (ERE)-related sequences, however, the molecular 
mechanisms still remained to be elucidated (Elstner et a l , 1998.). Therefore, the 
main purpose of the next chapter was to investigate whether there was any 
relationship between the promotion/induction of apoptosis and the PPARy. We 
would like to transiently transfect the NPA cells and to examine the PPARy 
activity when treated with PPT and DPN. Also, we would like to investigate 
further whether the PPARy ligands were involved in the proliferation and 
apoptotic effect of PPT and DPN, in which we could further trace the downstream 
molecular mechanisms of the apoptotic pathway of thyroid cancer cells. 
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Chapter Four 
The relationship between PPARy and Estrogen 
Receptor and the regulation of the apoptosis in 
thyroid cancer cell lines 
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4.1 Introduction 
Peroxisome proliferator-activated receptors (PPARs) are a family of transcription 
factors that belong to the nuclear receptor superfamily. Transactivation follows 
ligand binding, nuclear localization and heterodimerization (Tontonoz et al., 1994) 
with the 9-cis retinoid acid receptor (RXR) (Mangelsdorf el al., 1990). In human 
breast cancer cells PPARy is expressed at high levels and is functionally 
responsive to synthetic and natural ligands (Kilgore et al., 1997). As for PPARy, 
many reports have shown its involvement in several metabolic pathways, in 
adipocyte differentiation and in the growth inhibition of different cancer cell lines. 
(Lowell BB et al., 1999). In addition, PPARy promotes terminal differentiation of 
malignant breast epithelial cells in vitro and induces morphologic changes 
associated with apoptosis and fibrosis in breast tumor cells injected in mice 
(Elstner E. et al., 1998). PPARy expression has been reported in both primary and 
metastatic breast cancer where transactivation has been reported to induce 
differentiation (Mueller et al., 1998) and apoptosis (Elstner et al., 1998). 
In addition, much attention has been focused on the PPARy ligands and its 
regulation and involvement in carcinogenesis. Ligands for PPARy inhibit the 
growth of breast, prostate and colon cancer cells (Kitamura S et al., 1999, 
Brockman J A et a l , 1998 and Elstner E et al., 1998). In addition, they induce 
growth arrest through apoptosis in choriocarcinoma, lung cancer and pancreatic 
cancer cells. However, to our knowledge, the effect of 15-deoxy-A12,14-
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prostagladin J2 (15d-PGJ2) and other PPARy ligands on human thyroid cells has 
not been previously reported. 
15d-PGJ2 is one of PPARy natural ligands and it is a downstream metabolite of 
PGD2 and is produced by dehydration of Prostaglandin D2(PGD2). It has an 
antiproliferative activity on human hepatoma cell lines (Toyoda M et al , 2002). 
The well-known ligands for PPAR are synthetic anti-diabetic thiazolidinediones 
and 15-PGJ2 (Forman et al., 1995), but also include a large number of 
polyunsaturated fatty acids, among which are arachidonic acid metabolites such 
as 15(S)-HETE. 15(S)-HETE binds as a ligand to PPAR transcription factors and 
it is an effector of apoptosis (Pattabhiraman et al , 2003). 13S-H0DE is also one 
of the PPARy ligands which binds to PPARy, increases PPARy activation, and 
up-regulates PPARy expression in colorectal cancer cells (Imad et al , 2003). 
PPARy is an important signaling receptor for 135-HODE-induced apoptosis. 
Therefore, PPARy ligands play an important role in regulation of growth and 
apoptotsis of the cancer cell lines. 
As mentioned in the previous chapter, many studies have shown that estrogen 
receptor a (ERa) plays an important role in the development of various cancers. 
However, ERp has a differential effect on proliferation as compared with ERa. 
ERp has shown to inhibit proliferation of cancer cells and it may act as a tumor 
suppressor (Iwao et a l , 2000). Upon ligand binding, ERs undergoes a 
conformational change allowing transcriptional regulation of target genes (Jensen 
EV et a l , 1995). Both ERa and ERp belong to the large nuclear steroid/thyroid 
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hormone receptor family, they contain similar architecture of four interacting 
domains. This suggests that ERp can recognize and bind to the same ERE as ERa. 
In these years, an increasing physiologic significance has been attributed to the 
relationships among nuclear receptors. Both ER and PPARy play important roles 
in cell proliferation and apoptosis of cancer cells. 
ERa, ERp and PPARy are important nuclear receptors in the role of apoptosis and 
tumor development, also, the PPARy ligands, 15d-PGJ2, 15-HETE, 13S-H0DE 
are shown to be important regulators in carcinogenesis. As experiments shown in 
the previous chapter, PPT, ERa-specific agonist, enhanced the proliferation of 
thyroid cancer cells and thus reduced the apoptosis. Unlike ERa, DPN, ERp-
specific agonist, inhibited cell proliferation and promoted the apoptosis. Therefore, 
in this chapter, we would like to further investigate the effect of ERa agonist PPT 
and ERP agonist DPN in the regulation of PPARy activity in thyroid cancer cells. 
We would like to explore if there was any relationship between the 
promotion/induction of apoptosis by ERs and the levels of PPARy ligands. Two 
experiments had been performed: (i) the PPARy activity was measured by 
transient transfection assay, and (ii) the PPARy ligands (15d-PGJ2, 15-HODE, 
13S-H0DE) levels were measured by the 15d-PGJ2 enzyme immunoassays. 
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4.2 Methods 
4.2.1 Transient transfection 
NPA cells were transiently transfected with pFATP-(PPRE)3-tkLuc vector, 
pGL3一basic vectors and pGL3一control vectors. The procedures had been 
described in Chapter 2. Briefly，NPA cells were seeded at 5x10^ per well in a six-
well plate (Becton Dickson Labware, Franklin Lakes, NJ) and incubated overnight 
to allow cells to attach to the plate. 2|j,g vectors was mixed with 8|il Lipofectamin 
(Invitrogen, Carlsbad, CA) and 200^il RPMI 1640 (serum free) in a 1.5ml tube for 
45 minutes while the cells were washed with PBS twice and incubated in serum-
free RPMI 1640. After 45 minutes, 800|il MEM (serum free) was added into the 
1.5ml tube, and mixed gently and thoroughly. After treating with the transfection 
mixture solution for 6 hours, the cells were incubated in fresh RPMI1640 (with 
10% FBS). The cells were collected 72 hours after the transfection (Sherman, and 
Itzhaki, et al, 2002). 
4.2.2 Luciferase Assay 
Transfected NPA cells (10^ cells/well) were seeded into 6-well plates the day 
before transfection. Cells were transfected with 2|ig of PPAR-y-responsive 
reporter plasmid pFATP-(PPRE)3-tkLuc vector ((FATP-derived PPAR y response 
element with firefly luciferase gene under the control of a thymidine kinase 
promoter) per well by Lipofectamine (Invitrogen, Carlsbad, CA). The transient 
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transfection procedure had been described previously in chapter 2. 2\ig 
pGL3_basic vectors, or pGL3_control vectors were transfected to serve as a 
negative or positive control. Luciferase assay system (Promega, Madison, WI) 
was used in this part of study. Cells were collected 48 hours after transfection. 
After washing the cells with PBS twice, 200|il lysis buffer was added into each 
well and the cells were extracted from the plate by a scraper. The lysis solution 
was then transferred into a microcentrifuge tube and incubated on ice. After 
centrifuging at 14000rpm for 2 minutes (4 oC)，the supematants were aspirated to 
a new tube. 20|il cell lysate together with 65|il of Luciferase assay reagent was 
added into a well in a 96-well plate. The light intensity of each well was measured 
by a luminometer (Molecular Derices, Fullerton, CA). All experiments were 
performed at least three times in each plasmid. 
4.2.3 15d-PGJ2 ELISA assay 
Levels of 15d-PGJ2 were examined by enzyme immunoassay (EIA) as described 
earlier in chapter 2. NPA cells were seeded at lO* cells/200uL in 96-well plates 
and incubated overnight to allow cells to attach to the plate. In brief, NPA cells 
were treated with PPT (OuM, O.luM, 0.5uM, luM, 5uM) and DPN (OuM, O.luM, 
0.5uM, luM, 5uM) for 48 hours. After 48-hr of treatments, lOOuL of six 15d-
PGJ2 standards (with concentration of 2200,000, 50,000, 12,500, 3,125, 781 and 
195 pg/L) and lOOuL of cell culture medium from each sample were aliquot into 
each well. 50uL of blue conjugate and 50uL of yellow antibody then added to 
each well. The plate was incubated at room temperature on a plate shaker for 2 
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hours at ~500rpm. After incubation, emptied and washed the wells three times by 
adding 400uL of wash solution. Then, 200uL of the pNpp substrate solution was 
added to every well and incubated at 37C for 3 hours. 50uL After incubation, 
50uL of stop solution was added to every well and the plate were read 
immediately at optical density at 405nm with correction between 570-590nm. The 
level of 15d-PGJ2 of each sample was then calculated compared to the untreated 
cells. 
4,2.4 15S-HETE ELISA assay 
Levels of 15S-HETE were examined by enzyme immunoassay (EIA) as described 
earlier in chapter 2. NPA cells were seeded at lO* cells/200uL in 96-well plates 
and incubated overnight to allow cells to attach to the plate. In brief, NPA cells 
were treated with PPT (OuM, O.luM, 0.5uM, luM, 5uM) and DPN (OuM, O.luM, 
0.5uM, luM, 5uM) for 48 hours. After 48-hr of treatments, lOOuL of six 15S-
HETE standards (with concentration of 20,000, 5,000, 12,500, 1,250, 312.5 and 
78.12 pg/L) and lOOuL of cell culture medium from each sample were aliquot into 
each well. 50uL of blue conjugate and 50uL of yellow antibody then added to 
each well. The plate was incubated at room temperature for 18 hours at 4°C. After 
incubation, emptied and washed the wells three times by adding 400uL of wash 
solution. Then, 200uL of the pNpp substrate solution was added to every well and 
incubated at 37C for 1 hour without shaking. 50uL After incubation, 50uL of stop 
solution was added to every well and the plate were read immediately at optical 
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density at 405nm with correction between 570-590nm. The level of 15S-HETE of 
each sample was then calculated compared to the untreated cells. 
4.2.5 13S-HODE ELISA assay 
Levels of 13S-HODE were examined by enzyme immunoassay (EIA) as described 
earlier in chapter 2. NPA cells were seeded at lO* cells/200uL in 96-well plates 
and incubated overnight to allow cells to attach to the plate. In brief, NPA cells 
were treated with PPT (OuM, O.luM, 0.5uM, luM, 5uM) and DPN (OuM, O.luM, 
0.5uM, luM, 5uM) for 48 hours. After 48-hr of treatments, lOOuL of five 13S-
HODE standards (with concentration of 1,000，250, 62.5，15.6 and 3.9 ng/mL) and 
lOOuL of cell culture medium from each sample were aliquot into each well. 50uL 
of blue conjugate and 50uL of yellow antibody then added to each well. The plate 
was incubated at room temperature on a plate shaker for 2 hours at ~500rpm. 
After incubation, emptied and washed the wells three times by adding 400uL of 
wash solution. Then, 200uL of the pNpp substrate solution was added to every 
well and incubated at 37C for 2 hour without shaking. 50uL After incubation, 
50uL of stop solution was added to every well and the plate were read 
immediately at optical density at 405nm with correction between 570-590nm. 




4,3.1 PPT，ERa-agonist, increased thyroid cancer cell proliferation and 
caused the decrease the level of PPARy ligands. 
15d-PGJ2, 15S-HETE and 13S-H0DE Enzyme Immunoassay Kits were used to 
determine the levels of 15d-PGJ2, 15S-HETE and 13S-H0DE, respectively, in 
NPA cells treated with PPT (OuM, O.luM, 0.5uM, luM，5uM) and DPN (OuM, 
0.1 uM, 0.5uM, luM, 5uM) for 48 hours. 15d-PGJ2, 15S-HETE and 13S-H0DE 
were ligands of PPARy and it was assumed that the ERa-agonist PPT, which 
showed to enhance the proliferation of NPA cells and thus reduced the apoptosis, 
would cause an decrease in the levels of PPARy ligands 15d-PGJ2, 15S-HETE 
and 13S-HODE. Whereas DPN the ERp-agonist, which showed to inhibit cell 
proliferation of thyroid cancer cells and promoted the apoptosis, was assumed to 
increase the levels of PPARy ligands 15d-PGJ2, 15S-HETE and 13S-H0DE. 
Consistent with our MTT and apoptotic result, the level of 15d-PGJ2 when treated 
with PPT (OuM, O.luM, 0.5uM, luM, 5uM) for 48 hours had shown to be 
decrease (figure 4.1). In NPA cells, the level of 15d-PGJ2 was significantly 
decreased by PPT (figure 4.1). Treatment with PPT caused a significant reduction 
J 
at around 50% in the level of 15d-PGJ2 with concentrations of O.luM (0.493 土 
0.030)，0.5uM (0.515 土 0.041)，luM (0.435 士 0.066) and 5uM (0.406 土 0.035) 
when compared to the untreated NPA cells f**P < 0.01). Data were represented 
as means 士 S.D. of 3 sets of experiments; bars, SD. 
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Similar to the result of 15d-PGJ2, the result of the level of 15S-HETE when 
treated with PPT (OuM, O.luM, 0.5uM, luM, 5uM) for 48 hours has shown to be 
decrease in figure 4.2. In NPA cells, the level of 15S-HETE was significantly 
decreased by PPT. Treatments of PPT caused a reduction (about 20-35%) in the 
level of 15S-HETE with concentrations of O.luM (0.785 土 0.035), 0.5uM (0.821 土 
0.059), luM (0.693 士 0.048) and 5uM (0.647 士 0.059) when compared to the 
untreated NPA cells (value of control = 1.00). When compared to the level of 
15d-PGJ2 of NPA cells with PPT, the level of 15S-HETE showed less reduction. 
f*P < 0.05). Data were represented means士 S.D. of 3 sets of experiments; bars, 
SD. 
Next, in figure 4.3, it showed the result of the level of 13S-H0DE in cells treated 
with PPT (OuM, O.luM, 0.5uM, luM, 5uM) for 48 hours. In NPA cells, the level 
of 13S-HODE was significantly decreased by PPT. Treatment with PPT caused a 
(about 60%) reduction in the level of 15d-PGJ2 with concentrations of O.luM 
(0.359 土 0.078), 0.5uM (0.376 土 0.049)，luM (0.317 士 0.052) and 5uM (0.286 土 
0.032) when compared to the untreated NPA cells (value of control = 1.00). 
Among the levels of three different PPARy ligands in the cells treated with PPT, 
the level of 13S-H0DE had showed the highest reduction in thyroid cancer cells. 
f*P < 0.05’ **P<(9力7). Data were represented means士 S.D. of 3 sets of 
experiments; bars, SD. 
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Figure 4.1 Changes in the levels of 15d-PGJ2 in NPA cells treated with PPT. 
The levels of 15d-PGJ2 in response to PPT treatment (OuM, O.luM, 0.5uM, luM, 
5uM) for 48 hours. It showed that there were significant differences in the levels 
of 15d-PGJ2 among treatments < 0.01) when compared to control 
(untreated cells). Data were represented means土 S,D. of 3 sets of experiments; 
bars, SD. 
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Figure 4.2 Changes in the levels of 15S-HETE in NPA cells treated with PPT. 
The levels of 15S-HETE in response to PPT treatment (OuM, 0.1 uM, 0.5uM, luM, 
5uM) for 48 hours. It showed that there was significant differences in the levels of 
15S-HETE among treatments < 0.01) (*P<0.05j when compared to control 
(untreated cells). Data were represented means± S.D. of 3 sets of experiments; 
bars, SD. 
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Figure 4.3 Changes in the levels of 13S-H0DE in NPA cells treated with PPT. 
The levels of 13S-HODE in response to PPT treatment (OuM, O.luM, 0.5uM, luM, 
5uM) for 48hours. It showed that there was significant differences in the levels of 
13S-HODE among treatments f**P < 0.01) ('^P<0.05) when compared to control 
(untreated cells). Data were represented means土 S.D. of 3 sets of experiments; 
bars, SD. 
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4.3.2 DPN, ERfi-agonist, inhibited thyroid cancer cell proliferation, induced 
apoptosis and caused the increase the level of PPARy ligands. 
From the last section it had been shown that the ERa-agonist PPT, which showed 
to enhance the proliferation of NPA cells and thus reduced the apoptosis, caused a 
decrease in the levels of PPARy ligands 15d-PGJ2, 15S-HETE and 13S-H0DE. 
Whereas DPN the ERp-agonist, which showed to inhibit cell proliferation of 
thyroid cancer cells and promoted the apoptosis, appeared to increase the levels of 
PPARy ligands 15d-PGJ2, 15S-HETE and 13S-H0DE. 
Consistent with our MTT and apoptotic result in chapter three, the result of the 
level of 15d-PGJ2 when treated with DPN (OuM, O.luM, 0.5uM, luM, 5uM) for 
48 hours was shown to be increase in figure 4.4. In NPA cells, the level of 15d-
PGJ2 was increased by DPN (figure 4.4). Treatment with PPT caused a significant 
(around 20%) increase in the level of 15d-PGJ2 with concentrations of O.luM 
(1.20 土 0.040)，0.5uM (1.149 土 0.025) and luM (1.144 士 0.049) when compared 
to the untreated NPA cells (value of control = 1.00). Treatment with DPN 
concentration at 5uM had no effect as compared to the untreated cells. < 0.05). 
Data were represented means士 S.D. of 3 sets of experiments; bars, SD. 
Similar to the result of 15d-PGJ2, the result of the level of 15S-HETE when 
treated with DPN (OuM, O.luM, 0.5uM, luM, 5uM) for 48 hours had shown to be 
increase in figure 4.5. In NPA cells, the level of 15S-HETE was significantly 
increased by DPN. Treatment with DPN caused a maximum (about 56%) increase 
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in the level of 15S-HETE with concentrations of luM (1.566 士 0.12), when 
compared to the untreated NPA cells (the value of control = 1.00). When 
compared to the level of 15d-PGJ2 of NPA cells with DPN, the level of 15S-
HETE showed an increase at luM DPN only. (**P < 0,01). Data were 
represented means士 S.D. of 3 sets of experiments; bars, SD. 
Next, in figure 4.6，it showed the level of 13S-H0DE in cells treated with DPN 
(OuM, O.luM, 0.5uM, luM, 5uM) for 48 hours. In NPA cells, the level of 13S-
HODE was significantly increased by DPN. Treatments of DPN caused an (62-
90%) increase in the level of 15d-PGJ2 with concentrations of O.luM (1.895 土 
0.058), 0.5uM (1.830 土 0.049)，luM (1.821 士 0.053) and 5uM (1.629 士 0.032) 
when compared to the untreated NPA cells (the value of control 二 1.00). Among 
the levels of three different PPARy ligands in cells treated with DPN, the level of 
13S-H0DE had showed the highest levels in thyroid cancer cells 尸 < 0.01). 
Data represent means 土 S.D. of 3 sets of experiments; bars, SD. 
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Figure 4.4 Changes in the levels of 15d-PGJ2 
in NPA cells treated with DPN 
The levels of 15d-PGJ2 in response to DPN treatments (OuM, O.luM, 0.5uM, luM’ 
for 48 hours. It showed that there were significant differences in the levels 
of 15d-PGJ2 among treatments f*P < 0.05) when compared to control {untreated 
cells). Data were represented means土 S.D. of 3 sets of experiments; bars, SD. 
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Pigure 4.5 Changes in the levels of 15S-HETE in NPA cells treated with DPN. 
The levels of 15S-HETE in response to DPN treatments (OuM, O.luM, 0.5uM, 
I 讽 5uM) for 48 hours. It showed that there were significant differences in the 
levels of 15S-HETE among treatments f**/' < 0.01) when compared to control 
(untreated cells). Data were represented means± S.D. of 3 sets of experiments; 
bars, SD. 
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Figure 4.6 Changes in the levels ofl3S-HODE in NPA cells treated with DPN. 
The levels of 13S-H0DE in response to DPN treatment (OuM, O.luM, 0.5uM, luM, 
5uM) for 48 hours. It showed that there were significant differences in the levels 
of 13S-H0DE among treatments < 0.01) when compared to control 
{untreated cells). Data were represented means土 S,D. of 3 sets of experiments; 
bars, SD. 
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PPT did not alter the transcriptional activity of PPARy. 
To characterize the transcriptional regulation of PPARy by ERa-agonist PPT and 
ERp-agonist DPN, we conducted a transient transfection and luciferase reporter 
assay. NPA cells were transiently transfected with the PPARy responsive reporter 
plasmid pFATP-(PPRE)3-tkLuc (FATP-derived PPARy responsive element with 
firely luciferase gene under the control of a thymidine kinase promoter), 
pGL3basic vecter (as negative control) or pGL3 control vector (as positive 
control). The luciferase assay indicated that pFATP-(PPRE)3-tkLuc and pGL3 
control activated luciferase expression above the pGL3-Basic control. 
The luciferase-based reporter-gene activation assay was to assess whether PPT 
could increase the PPARy transcriptional activation. The PPARy responsive 
element (PPRE) isolated from the fatty acid transporter protein (FATP) gene was 
used to drive the expression of the reporter gene. However, upon PPT treatment in 
NPA cells at the concentration of luM for 24hr, 48hr and 72hr, it showed that 
there was no effect on the luciferase activity on the three time-points. PPT did not 
alter the transcriptional activity of PPARy (Figure 4.7). When NPA cells treated 
with luM of DPN at 24hr，48hr and 72 hrs, it showed that DPN treatment 
enhanced the transcriptional activity of PPARy for 3 folds at 48hr and 72hr-
timepoint. 
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Figure 4.7 PPARy activity in NPA cells. 
PPARy activity was analyzed in thyroid cancer cells NPA after 24hr, 48hr and 
72hrs of PPT and DPN treatments using a luciferase-based reporter-gene 
activation assay. Cells were transiently transfected with either PPRE-tk-Luc or tk-
Luc PGL3 basic plasmid, or pGLS control plasmid as positive control and pGLS 
basic plasmid as negative control of transfection efficiency and luciferase activity. 
After PPT and DPN treatments under different timepoints 24hr, 48hr and 72hr, 
the luciferase activity was assayed using luciferase assay kit as described in 
Materials and Methods. The data were represented as mean 士SD (**P>0.01) for 
triplicate determinations for each group. Experiments were repeated three times 
with similar results. 
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4.4 Discussion 
There are an increasing number of publications describing the role of PPARy in 
human malignancies including thyroid, breast, lung, gastric, colon, and prostate 
cancers. Although some experiments show a tumor-promoting role of PPARy 
ligands in certain tumors such as colon cancer, the majority of reports demonstrate 
an inhibitory effect of PPARy ligands on tumor growth (Chang and Szabo, 2000; 
Tsubouchi et a l , 2000; Wakino et al., 2001; Yang and Fmcht，2001; Yin et al., 2001; 
Masamune et a l , 2002; Keshamouni et al., 2004). Recently various PPARy ligands 
have been discovered and studies have shown that their signal transduction 
pathways may not be the same. Among these PPARy ligands, 15d-PGJ2, 15S-HETE, 
13S-H0DE have been reported to promote terminal differentiation and 
morphological changes to well-differentiated and less malignant state. However, the 
molecular mechanism responsible is not well understood. In our study in chapter 
two, we first confirmed that PPT, ERa-agonist, enhanced the proliferation of 
thyroid cancer cells and thus reduced the apoptosis. Unlike PPT, DPN, ERp agonist, 
inhibited the cell proliferation and promoted the apoptosis. 
In this chapter，we had shown that there was a relationship between the promotion 
and induction of apoptosis and the PPARy- As the PPARy ligands binding, PPARy 
heterodimerized with the retinoid X receptors (RXR), and bound to the PPARy 
responsive elements in the promoter of the target genes. Activation of receptor 
induced certain characteristics of differentiation, cell-cycle arrest and induction of 
apoptosis. Firstly, we had performed PPARy-ligand-enzyme immunoassay (EIA): 
15d-PGJ2, 15S-HETE and 13S-H0DE ELISA assay in order to observe the level of 
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PPARy ligands and the effect of the PPARy activity. After the PPARy-ligand 
ELISA assay, transient transfection and luciferase activity assay had been 
performed to examine the transcriptional activity of PPARy. 
When NPA cells treated with PPT, it showed tthat there were significant decrease 
sin the PPARy ligands 15d-PGJ2, 15S-HETE and 13S-H0DE. Combining with the 
previous MTT and apoptotic results, we proposed that PPT, the ERa-agonist, 
increased thyroid cancer cells proliferation probably via decreasing the level of 
PPARy ligands. When NPA cells treated with DPN, it showed that there were 
significant increases in the PPARy ligands 15d-PGJ2, 15S-HETE and 13S-H0DE. 
We proposed that DPN, the ERp-agonist, induced apoptosis by increasing the levels 
of PPARy ligands. From the results of the transient tranfection and luciferase 
activity assay, it showed that PPT had no effect on the transcriptional activity of 
PPARy while DPN enhanced it significantly. Therefore, it was possible that ERa-
agonist and ERp-agonist regulated the proliferation or apoptosis of thyroid cancer 
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5.1 Summary of results 
1. ERa, ERp and PPARy were expressed in thyroid cancer cells. 
2. PPT, an ERa-selective agonis, increased the cell proliferation in MTT assay. 
3. PPT reduced the apoptosis measured by Cell Death ELISAplus assay. 
4. PPT decreased the PPARy-ligands 15d-PGJ2, 15S-HETE and 13S-H0DE, and 
all three were measured by the PPARy-ligand ELISA (EIA) assay. 
5. PPT had no effect on the PPARy transcriptional activity in the transient 
tranfection and luciferase activity assay. 
6. DPN, an ERp-selective agonist, inhibited cell proliferation measured by MTT 
assay. 
7. DPN promoted the apoptosis measured by Cell Death ELISAplus assay. 
8. DPN increased the PPARy-ligands 15d-PGJ2，15S-HETE and 13S-HODE, 
and all three were measured by PPARy-ligand ELISA (EIA) assay. 
9. DPN increased the PPARy transcriptional activity in the transient tranfection 
and luciferase activity assay. 
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5.2 Conclusion 
In conclusion, PPT, the ERa-selective agonist, increased thyroid cancer cell 
proliferation probably via decreasing the level of PPARy-ligands 15d-PGJ2, 15S-
HETE and 13S-H0DE whereas DPN, ERp-selective agonist, induced apoptosis 
by increasing the levels of PPARy-ligands inc;uding 15d-PGJ2, 15S-HETE and 
13S-H0DE and the PPARy transcriptional activity. Therefore, it is possible that 
PPT and DPN may regulate the proliferation or apoptosis of thyroid cancer cells 
via a pathway related to the production of PPARy ligands and/or the activation of 
PPARy. 
5.3 Future prospects 
Our present study has explored the relationship between ER and PPARy and the 
regulation in proliferation and apoptosis of thyroid cancer cells. It is worthwhile to 
further investigate the effects of PPT and DPN on NPA cells in two conditions: 1) 
Down-regulation of PPARy gene by using siRNA, or 2) Up-regulation of PPARy 
gene by stably transfection. Also, our study may also provide the novel idea for 
the therapy of thyroid cancer. However, at present our findings are all obtained in 
in vitro experimental models, which may not be the same as in vivo. Therefore, it 
will be important to confirm the result in an in vivo model of thyroid cancer, 
particularly the model induced by PPT and DPN treatment and their effects. 
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